

# **Quotation Advert**

**Opening Date:** 

26/11/2024

**Closing Date:** 

29/11/2024

**Closing Time:** 

11:00

**INSTITUTION DETAILS** 

Institution Name:

King Cetshwayo District Office

Province:

KwaZulu-Natal

Department of entity:

Department of Health

Division or section:

**Supply Chain Management** 

Place where goods/

KING CETSHWAYO DISTRICT OFFICE

**Date Submitted:** 

26/11/2024

**ITEM CATEGORY AND DETAILS** 

**Quotation number:** 

ZNQ/194/KCD/24-25

**Item Category:** 

Goods

Item Description:

ART BAROMETER AND CHARTS

Quantity (if supplies):

**COMPULSORY BRIEFING SESSION / SITE VISIT** 

**Select Type:** 

Not applicable

Date:

Not applicable

Time:

Not applicable

Venue:

Not applicable

**QUOTES CAN BE COLLECTED FROM:** 

KZN Health Website Only

**QUOTES SHOULD BE DELIVERED TO:** 

**QUOTATION MUST BE DEPOSITED ON THE** 

TENDER BOX: 2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA -

**EMPANGENI RAIL, 3910** 

**ENQUIRIES REGARDING ADVERT MAY BE DIRECTED TO:** 

Name:

Siphiwo Ngema

Email:

Siphiwo.ngema@kznhealth.gov

Contact number: 035 787 6287

Finance Manager: Mrs SL MSANI

Finance Manager Signature



AND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA - EMPANGENI RAIL, 3910  DESCRIPTION:  ART BAROMETER AND CHARTS  CONTRACT PERIOD (IF APPLICABLE):  DISTRICT OFFICE BUILDING: 1ST FLOOR; 2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA - EMPANGENI RAIL, 3910  ENQUITE NUMBER: 2NQ / KCD 1/194 /24 .25 VALIDITY PERIOD: 90 DAYS  DESCRIPTION:  ART BAROMETER AND CHARTS  CONTRACT PERIOD (IF APPLICABLE):  DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR; 2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON:  MIN S NGEMA  TELEPHONE NUMBER: 035 787 6287  EMAIL ADDRESS:  EMAIL ADDRESS:  BIDIWO. ngema@kznhealth.gov.za  BIdders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.  QUOTATIONS MUST BE SUBMITTED ON THE OFFICIAL FORMS - (NOT TO BE RETYPED)
PHYSICAL ADDRESS:  2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA - EMPANGENI RAIL, 3910  QUOTE NUMBER:  ZNQ /KCD / 194 1/24 .25 VALIDITY PERIOD: 90 DAYS  DATE ADVERTISED: 26/11/2024 CLOSING DATE: 29/11/2024 CLOSING TIME: 11:00  DESCRIPTION: ART BAROMETER AND CHARTS  CONTRACT PERIOD: (IF APPLICABLE): ONCE-OFF  DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR; 2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON: Mr S NGEMA TELEPHONE NUMBER: 035 787 6287  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr WW MKHABELE TELEPHONE NUMBER: 035 787 6269  EMAIL ADDRESS: TELEPHONE NUMBER: 035 787 6269  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
QUOTE NUMBER: ZNQ
DATE ADVERTISED: 26/11/2024 CLOSING DATE: 29/11/2024 CLOSING TIME: 11:00  DESCRIPTION: ART BAROMETER AND CHARTS  CONTRACT PERIOD (IF APPLICABLE): ONCE-OFF  DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR; 2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON: Mr S NGEMA TELEPHONE NUMBER: 035 787 6287  EMAIL ADDRESS: siphiwo.ngema@kznhealth.gov.za  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr MV MKHABELE TELEPHONE NUMBER: 035 787 6269  E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
DESCRIPTION:  ART BAROMETER AND CHARTS  CONTRACT PERIOD (IF APPLICABLE):  DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR;2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON: Mr S NGEMA  TELEPHONE NUMBER: O35 787 6287  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr MV MKHABELE  TELEPHONE NUMBER: O35 787 6269  E-MAIL ADDRESS: TELEPHONE NUMBER: TELEPHONE NUMBER: O35 787 6269  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.
CONTRACT PERIOD (IF APPLICABLE):  DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR;2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON: Mr S NGEMA  TELEPHONE NUMBER: O35 787 6287  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr MV MKHABELE  TELEPHONE NUMBER: O35 787 6269  E-MAIL ADDRESS: TELEPHONE NUMBER: O35 787 6269  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS): KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR;2ND LOOD AVE, CNR CHROME CRESCENT AVE, KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO: CONTACT PERSON: Mr S NGEMA TELEPHONE NUMBER: 035 787 6287  E-MAIL ADDRESS: Siphiwo.ngema@kznhealth.gov.za  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr MV MKHABELE TELEPHONE NUMBER: 035 787 6269  E-MAIL ADDRESS: TELEPHONE NUMBER: 035 787 6269  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
KING CETSHWAYO DISTRICT OFFICE BUILDING: 1ST FLOOR;2ND LOOD AVE, CNR CHROME CRESCENT AVE,  KULEKA EMPANGENI RAIL 3910  ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO:  CONTACT PERSON: Mr S NGEMA  E-MAIL ADDRESS: Siphiwo.ngema@kznhealth.gov.za  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO:  CONTACT PERSON: Mr MV MKHABELE  E-MAIL ADDRESS: TELEPHONE NUMBER: 035 787 6269  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
ENQUIRIES REGARDING THE QUOTE MAY BE DIRECTED TO:  CONTACT PERSON: Mr S NGEMA  E-MAIL ADDRESS: siphiwo.ngema@kznhealth.gov.za  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO:  CONTACT PERSON: Mr MV MKHABELE  E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
CONTACT PERSON: Mr S NGEMA  E-MAIL ADDRESS: siphiwo.ngema@kznhealth.gov.za  ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO: CONTACT PERSON: Mr MV MKHABELE  E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
ENQUIRIES REGARDING TECHNICAL INFORMATION MAY BE DIRECTED TO:  CONTACT PERSON: Mr MV MKHABELE  E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
CONTACT PERSON: Mr MV MKHABELE TELEPHONE NUMBER: 035 787 6269  E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
E-MAIL ADDRESS: marvin.mkhabele@kznhealth.gov.za  Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration.  The quote box is open from 08:00 to 15:30.
The quote box is open from 08:00 to 15:30.
QUOTATIONS MUST BE SUBMITTED ON THE OFFICIAL FORMS (NOT TO BE RETYPED)
THIS QUOTE IS SUBJECT TO THE PREFERENTIAL PROCUREMENT POLICY FRAMEWORK ACT AND THE PREFERENTIAL PROCUREMENT REGULATIONS, 2022, THE GENERAL CONDITIONS OF CONTRACT.
THE FOLLOWING PARTICULARS OF BIDDER MUST BE FURNISHED  (FAILURE TO DO SO MAY RESULT IN YOUR QUOTE BEING DISQUALIFIED)
NAME OF BIDDER:
E-MAIL ADDRESS:
POSTAL ADDRESS:
STREET ADDRESS:
OTTALET ADDITION.
TELEPHONE NUMBER: FACSIMILE NUMBER:
TELEPHONE NUMBER
TELEPHONE NUMBER: FACSIMILE NUMBER:
TELEPHONE NUMBER: FACSIMILE NUMBER: SARS PIN:  VAT REGISTRATION NUMBER (If VAT vendor):
TELEPHONE NUMBER: FACSIMILE NUMBER: SARS PIN:



QUOTE NUMBE	R: ZNQ	,KCD	▼,194 ,24 <u>-</u> 25	*				
DESCRIPTION:	ART B	AROMETI	ER AND CHARTS					
THE BELOW PI PROCUREMEN			. BE ALLOCATED IN COMPLIANCE WITH THE DEPARTI M PPP):	MENTAL PR	EFERENCE	POINTS A	LLOCA	TED
RDP Goal: Full points a	llocated to promote	enterprises owned l	by Youth			2	20	
		I		COUNTRY OF	PR	ICE		
ICN NUMBER	QUANTITY	UNIT OF MEASURE	DESCRIPTION	BRAND & MODEL	MANUFACTUR E	R	c	
U4549844	5500	UNIT	Adult Clinical charts				Ť	
U5527193	150	UNIT	Barometer - Viral Load completion and					
			suppression					
U5527205	150	UNIT	Barometer - HIV and TB Cascades					
U5525757	150	UNIT	Chart - Art Drug Dosing for children 2022					
· •								
U5525769	150	UNIT	Chart - Viral Load monitoring for clients on					
, , , ,			TLD					
U5525771	150	UNIT	Chart - Management of confirmed					
			Virological failure					
U5525783	150	UNIT	Chart - Switching children on PI-Containing					
			regimen					
U5525795	150	UNIT	Chart- RE-initiating ART in no-pregnant clien					
-								
			IMPORTANT NOTES:	,		_		
			See attached Specification and Evaluation					
			Criteria					
			To deliver at King Cetshwayo District Office					
VALUE ADDED	TAX @ 15% (	Only if VAT V	/endor)					
TOTAL QUOTA	TION PRICE (	VALIDITY PE	RIOD 90 Days)					
S THE PRICE F	IRM?	,	PECIFICATION?			,	YEŞ /	NC.
			A.N.S. / S.A.B.S. SPECIFICATION?			`	YES /	NC
STATE DELIVEF NAME OF BIDDI	-	.G. 3 DAYS, 1	I WEEK) SIGNATURE OF BIDD	ER.		<del></del>		
AL MAIC OF DIDDI			[By signing this document		agree to all terms	and conditions	s]	



# STANDARD QUOTATION DOCUMENT FOR QUOTATIONS UP TO R1 000 000

# **CLARITY ON DECLARATION OF INTEREST SBD 4 (a)**

BIDDEK NAME								
	1 5000 17	TON ON DIOC COUR						
herself to perform rea	ct 103 of 1994 indicate	ide his or her employ	"No employee shall p	erform or engage himself or epartment, except with the				
Furthermore, in terms of the Public Service Regulations paragraph 13(c), "An employee shall not conduct business with any organ of state or be a director of a public or private company conducting business with an organ of state, inless such employee is in an official capacity a director of a company listed in schedule 2 and 3 of the Public Finance Management Act"								
Treasury Regulations 16A8.4 further indicates that "If a supply chain management official or other role player, or any close family member, partner or associate of such official or other role player, has any private or business interest n any contract to be awarded, that official or other role player must-(a) disclose that interest; and (b) withdraw from participating in any manner whatsoever in the process relating to that contract."								
		ARITY ON HOW TO		W-0-18-AM-11-12-11				
employed by the entir The Department may	e KZN Department of use other Computer A	Health, even if that pe Assisted Techniques to	verify possible interes	nip with any person by the procuring institution. st, should you be found to treated as non-responsive				
by Manguzi Hospital, disclose interest. The with any person who i	as long as that official refore the question is,	is employed by the D do you, or any persor N Department of Hea	epartment of Health, the connected with the bi	with interest is employed ne bidder is required to dder, have a relationship h particulars on Bidders				
	-		fisclose as directed, sh					
BIDDER SURNAME	AND INITIALS	SIGNATURE	DATE	<del></del>				



in submitting the accompanying bid, do hereby make



BIDDER'S DISCLOSURE

SBD 4

### PURPOSE OF THE FORM

Any person (natural or juristic) may make an offer or offers in terms of this invitation to bid. In line with the principles of transparency, accountability, impartiality, and ethics as enshrined in the Constitution of the Republic of South Africa and further expressed in various pieces of legislation, it is required for the bidder to make this declaration in respect of the details required hereunder.

Where a person/s are listed in the Register for Tender Defaulters and / or the List of Restricted Suppliers, that person will automatically be disqualified from the bid process.

### **BIDDER'S DECLARATION**

2.1. Is the bidder, or any of its directors / trustees / shareholders / members / partners or any person having a controlling interest 1 in the enterprise, employed by the state?

YES / NO

	FILL NAME	IDENTITY NUMBER	
	shareholders / members/ partners or any person having	ng a controlling interest in the enterprise, in table b	elow.
	ahanahaldan Incombant I	ay mamasia, and, is applicable, state chiployee has	uners or sole brobliefort directors t finistees t
2.1.1.	If so, furnish particulars of the names, individual identi	ity numbers, and if annlicable state employee nur	where of cala proprietori directors ( tweetons )

	I OLL MAINE		IDENTITY NUMBER	NAME OF STATE INSTITUTION	1
					Ì
2.2.	Do you, or any person connec	ted with the bidder, hav	e a relationship with any person who	is employed by the procuring institution <sup>2</sup> ?	YES / NO
2.2.1.	If so, furnish particulars:	·			
2.3,	Does the bidder or any of its d enterprise have any interest in	irectors / trustees / shar any other related enter	eholders / members / partners or any prise whether or not they are bidding	person having a controlling interest in the for this contract?	YES / NO
2.3.1.	If so, furnish particulars:				
3	DECLARATION				

### I, the undersigned,(name) the following statements that I certify to be true and complete in every respect:

- 3.1. I have read and I understand the contents of this disclosure: I understand that the accompanying bid will be disqualified if this disclosure is found not to be true and complete in every respect; 3.2.
- The bidder has arrived at the accompanying bid independently from, and without consultation, communication, agreement or arrangement with any competitor. However, communication between partners in a joint venture or consortium<sup>3</sup> will not be construed as collusive bidding.
- 3.4. In addition, there have been no consultations, communications, agreements or arrangements with any competitor regarding the quality, quantity, specifications, prices, including methods, factors or formulas used to calculate prices, market allocation, the intention or decision to submit or not to submit the bid, bidding with the intention not to win the bid and conditions or delivery particulars of the products or services to which this bid invitation
- 3.5. The terms of the accompanying bid have not been, and will not be, disclosed by the bidder, directly or indirectly, to any competitor, prior to the date and time of the official bid opening or of the awarding of the contract.
- 3.6. There have been no consultations, communications, agreements or arrangements made by the bidder with any official of the procuring institution in relation to this procurement process prior to and during the bidding process except to provide clarification on the bid submitted where so required by the institution; and the bidder was not involved in the drafting of the specifications or terms of reference for this bid.
- 3.7. I am aware that, in addition and without prejudice to any other remedy provided to combat any restrictive practices related to bids and contracts, bids that are suspicious will be reported to the Competition Commission for investigation and possible imposition of administrative penalties in terms of section 59 of the Competition Act No 89 of 1998 and or may be reported to the National Prosecuting Authority (NPA) for criminal investigation and or may be restricted from conducting business with the public sector for a period not exceeding ten (10) years in terms of the Prevention and Combating of Corrupt Activities Act No 12 of 2004 or any other applicable legislation.

I CERTIFY THAT THE INFORMATION FURNISHED IN PARAGRAPHS 1, 2 and 3 ABOVE IS CORRECT.

I ACCEPT THAT THE STATE MAY REJECT THE BID OR ACT AGAINST ME IN TERMS OF PARAGRAPH 6 OF PFMA SCM INSTRUCTION 03 OF 2021/22 ON PREVENTING AND COMBATING ABUSE IN THE SUPPLY CHAIN MANAGEMENT SYSTEM SHOULD THIS DECLARATION PROVE TO BE EAST.

7.0002	WILL COLLET OUT IN WARAGEWEN	3131EW SHOULD THIS DECLARATIO	N PROVE TO BE FALSE.
	-		
MANE OF PIPPER			
NAME OF BIDDER	SIGNATURE	POSITION	DATE

<sup>1</sup> The power, by one person or a group of persons holding the majority of the equity of an enterprise, alternatively, the person/s having the deciding vote or power to influence or to direct the course and decisions of the enterprise.

<sup>2 &</sup>quot;Procuring Institution" refers to all institutions under the Accounting Officer of the Department of Health.

<sup>3</sup> Joint venture or Consortium means an association of persons for the purpose of combining their expertise, property, capital, efforts, skill and knowledge in an activity for the execution of a contract



**GENERAL CONDITIONS OF CONTRACT** 

GCC

### NOTES

The purpose of this document is to:

- (i) Draw special attention to certain general conditions applicable to government bids, contracts and orders; and
- (ii) To ensure that clients be familiar with regard to the rights and obligations of all parties involved in doing business with government.

In this document words in the singular also mean in the plural and vice versa and words in the masculine also mean in the feminine and neuter.

- The General Conditions of Contract will form part of all bid/quotation documents and may not be amended.
- Special Conditions of Contract (SCC) relevant to a specific bid, should be compiled separately for every bid (if applicable) and will supplement the General Conditions of Contract. Whenever there is a conflict, the provisions in the SCC shall prevail.

### 1. Definitions

The following terms shall be interpreted as indicated:

- 1.1. "Closing time" means the date and hour specified in the bidding documents for the receipt of bids.
- "Contract" means the written agreement entered into between the purchaser and the supplier, as recorded in the contract form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
- 1.3. "Contract price" means the price payable to the supplier under the contract for the full and proper performance of his contractual obligations.
- 1.4. "Corrupt practice" means the offering, giving, receiving, or soliciting of any thing of value to influence the action of a public official in the procurement process or in contract execution.
- 1.5. "Countervailing duties" are imposed in cases where an enterprise abroad is subsidized by its government and encouraged to market its products internationally.
- "Country of origin" means the place where the goods were mined, grown or produced or from which the services are supplied. Goods are produced when, through manufacturing, processing or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
- 1.7. "Day" means calendar day
- 1.8. "Delivery" means delivery in compliance of the conditions of the contract or order.
- 1.9. "Delivery ex stock" means immediate delivery directly from stock actually on hand.
- 1.10. "Delivery into consignees store or to his site" means delivered and unloaded in the specified store or depot or on the specified site in compliance with the conditions of the contract or order, the supplier bearing all risks and charges involved until the supplies are so delivered and a valid receipt is obtained.
- 1.11. "Dumping" occurs when a private enterprise abroad market its goods on own initiative in the RSA at lower prices than that of the country of origin and which have the potential to harm the local industries in the RSA
- 1.12. "Force majeure" means an event beyond the control of the supplier and not involving the supplier's fault or negligence and not foreseeable. Such events may include, but is not restricted to, acts of the purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions and freight embargoes.
- 1.13. "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of any bidder, and includes collusive practice among bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the bidder of the benefits of free and open competition.
- 1.14. "GCC" means the General Conditions of Contract.
- 1.15. "Goods" means all of the equipment, machinery, and/or other materials that the supplier is required to supply to the purchaser under the contract.
- "Imported content" means that portion of the bidding price represented by the cost of components, parts or materials which have been or are still to be imported (whether by the supplier or his subcontractors) and which costs are inclusive of the costs abroad, plus freight and other direct importation costs such as landing costs, dock dues, import duty, sales duty or other similar tax or duty at the South African place of entry as well as transportation and handling charges to the factory in the Republic where the supplies covered by the bid will be manufactured.
- 1.17. "Local content" means that portion of the bidding price which is not included in the imported content provided that local manufacture does take place.
- 1.18. "Manufacture" means the production of products in a factory using labour, materials, components and machinery and includes other related value-adding activities.
- 1.19. "Order" means an official written order issued for the supply of goods or works or the rendering of a service.
- 1.20. "Project site," where applicable, means the place indicated in bidding documents.
- 1.21. "Purchaser" means the organization purchasing the goods.
- 1.22. "Republic" means the Republic of South Africa.
- 1.23. "SCC" means the Special Conditions of Contract.
- 1.24. "Services" means those functional services ancillary to the supply of the goods, such as transportation and any other incidental services, such as installation, commissioning, provision of technical assistance, training, catering, gardening, security, maintenance and other such obligations of the supplier covered under the contract.
- 1.25. "Written" or "in writing" means handwritten in ink or any form of electronic or mechanical writing.

### 2. Application

- 2.1. These general conditions are applicable to all bids, contracts and orders including bids for functional and professional services, sales, hiring, letting and the granting or acquiring of rights, but excluding immovable property, unless otherwise indicated in the bidding documents.
- 2.2. Where applicable, special conditions of contract are also laid down to cover specific supplies, services or works.
- Where such special conditions of contract are in conflict with these general conditions, the special conditions shall apply.

### 3. General

- 3.1. Unless otherwise indicated in the bidding documents, the purchaser shall not be liable for any expense incurred in the preparation and submission of a bid. Where applicable a non-refundable fee for documents may be charged.
- 3.2. With certain exceptions, invitations to bid are only published in the Government Tender Bulletin. The Government Tender Bulletin may be obtained directly from the Government Printer, Private Bag X85, Pretoria 0001, or accessed electronically from www.treasury.gov.za

### STANDARD QUOTATION DOCUMENT FOR QUOTATIONS UP TO R1 000 000



### 4. Standards

4.1. The goods supplied shall conform to the standards mentioned in the bidding documents and specifications.

### 5. Use of contract documents and information; inspection.

- 5.1. The supplier shall not, without the purchaser's prior written consent, disclose the contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the purchaser in connection therewith, to any person other than a person employed by the supplier in the performance of the contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.
- 5.2. The supplier shall not, without the purchaser's prior written consent, make use of any document or information mentioned in GCC clause 5.1 except for purposes of performing the contract.
- 5.3. Any document, other than the contract itself mentioned in GCC clause 5.1 shall remain the property of the purchaser and shall be returned (all copies) to the purchaser on completion of the supplier's performance under the contract if so required by the purchaser.
- 5.4. The supplier shall permit the purchaser to inspect the supplier's records relating to the performance of the supplier and to have them audited by auditors appointed by the purchaser, if so required by the purchaser.

### 6. Patent rights

6.1. The supplier shall indemnify the purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

### Performance security

- 7.1. Within thirty (30) days of receipt of the notification of contract award, the successful bidder shall furnish to the purchaser the performance security of the amount specified in SCC.
- 7.2. The proceeds of the performance security shall be payable to the purchaser as compensation for any loss resulting from the supplier's failure to complete his obligations under the contract.
- 7.3. The performance security shall be denominated in the currency of the contract, or in a freely convertible currency acceptable to the purchaser and shall be in one of the following forms:
  - (a) a bank guarantee or an irrevocable letter of credit issued by a reputable bank located in the purchaser's country or abroad, acceptable to the purchaser, in the form provided in the bidding documents or another form acceptable to the purchaser; or
  - (b) a cashier's or certified cheque
- 7.4. The performance security will be discharged by the purchaser and returned to the supplier not later than thirty (30) days following the date of completion of the supplier's performance obligations under the contract, including any warranty obligations, unless otherwise specified in SCC.

### 8. Inspections, tests and analyses

- 8.1. All pre-bidding testing will be for the account of the bidder.
- 8.2. If it is a bid condition that supplies to be produced or services to be rendered should at any stage during production or execution or on completion be subject to inspection, the premises of the bidder or contractor shall be open, at all reasonable hours, for inspection by a representative of the Department or an organization acting on behalf of the Department.
- 8.3. If there are no inspection requirements indicated in the bidding documents and no mention is made in the contract, but during the contract period it is decided that inspections shall be carried out, the purchaser shall itself make the necessary arrangements, including payment arrangements with the testing authority concerned.
- 8.4. If the inspections, tests and analyses referred to in clauses 8.2 and 8.3 show the supplies to be in accordance with the contract requirements, the cost of the inspections, tests and analyses shall be defrayed by the purchaser.
- 8.5. Where the supplies or services referred to in clauses 8.2 and 8.3 do not comply with the contract requirements, irrespective of whether such supplies or services are accepted or not, the cost in connection with these inspections, tests or analyses shall be defrayed by the supplier.
- 8.6. Supplies and services which are referred to in clauses 8.2 and 8.3 and which do not comply with the contract requirements may be rejected.
- 8.7. Any contract supplies may on or after delivery be inspected, tested or analyzed and may be rejected if found not to comply with the requirements of the contract. Such rejected supplies shall be held at the cost and risk of the supplier who shall, when called upon, remove them immediately at his own cost and forthwith substitute them with supplies which do comply with the requirements of the contract. Failing such removal the rejected supplies shall be returned at the suppliers cost and risk. Should the supplier fail to provide the substitute supplies forthwith, the purchaser may, without giving the supplier further opportunity to substitute the rejected supplies, purchase such supplies as may be necessary at the expense of the supplier.
- 8.8. The provisions of clauses 8.4 to 8.7 shall not prejudice the right of the purchaser to cancel the contract on account of a breach of the conditions thereof, or to act in terms of Clause 23 of GCC.

### 9. Packing

- 9.1. The supplier shall provide such packing of the goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packing, case size and weights shall take into consideration, where appropriate, the remoteness of the goods' final destination and the absence of heavy handling facilities at all points in transit.
- 9.2. The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the contract, including additional requirements, if any, specified in SCC, and in any subsequent instructions ordered by the purchaser.

### 10. Delivery and documents

- 10.1. Delivery of the goods shall be made by the supplier in accordance with the terms specified in the contract. The details of shipping and/or other documents to be furnished by the supplier are specified in SCC.
- 10.2. Documents to be submitted by the supplier are specified in SCC.

### 11. Insurance

11.1. The goods supplied under the contract shall be fully insured in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage and delivery in the manner specified in the SCC.



### Transportation

12.1. Should a price other than an all-inclusive delivered price be required, this shall be specified in the SCC.

### 13. Incidental services

- 13.1. The supplier may be required to provide any or all of the following services, including additional services, if any, specified in SCC:
  - (a) performance or supervision of on-site assembly and/or commissioning of the supplied goods;
  - (b) furnishing of tools required for assembly and/or maintenance of the supplied goods;
  - (c) furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied goods;
  - (d) performance or supervision or maintenance and/or repair of the supplied goods, for a period of time agreed by the parties, provided that this service shall not relieve the supplier of any warranty obligations under this contract; and
  - (e) training of the purchaser's personnel, at the supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the
- 13.2. Prices charged by the supplier for incidental services, if not included in the contract price for the goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the supplier for similar services.

### 14. Spare parts

- As specified in SCC, the supplier may be required to provide any or all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the supplier:
  - (a) such spare parts as the purchaser may elect to purchase from the supplier, provided that this election shall not relieve the supplier of any warranty obligations under the contract; and
  - (b) in the event of termination of production of the spare parts:
    - (i) Advance notification to the purchaser of the pending termination, in sufficient time to permit the purchaser to procure needed requirements; and
    - (ii) following such termination, furnishing at no cost to the purchaser, the blueprints, drawings, and specifications of the spare parts, if requested.

### 15. Warranty

- 15.1. The supplier warrants that the goods supplied under the contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials unless provided otherwise in the contract. The supplier further warrants that all goods supplied under this contract shall have no defect, arising from design, materials, or workmanship (except when the design and/or material is required by the purchaser's specifications) or from any act or omission of the supplier, that may develop under normal use of the supplied goods in the conditions prevailing in the country of final destination.
- 15.2. This warranty shall remain valid for twelve (12) months after the goods, or any portion thereof as the case may be, have been delivered to and accepted at the final destination indicated in the contract, or for eighteen (18) months after the date of shipment from the port or place of loading in the source country, whichever period concludes earlier, unless specified otherwise in SCC.
- 15.3. The purchaser shall promptly notify the supplier in writing of any claims arising under this warranty.
- 15.4. Upon receipt of such notice, the supplier shall, within the period specified in SCC and with all reasonable speed, repair or replace the defective goods or parts thereof, without costs to the purchaser.
- 15.5. If the supplier, having been notified, fails to remedy the defect(s) within the period specified in SCC, the purchaser may proceed to take such remedial action as may be necessary, at the supplier's risk and expense and without prejudice to any other rights which the purchaser may have against the supplier under the contract.

### 16. Payment

- 16.1. The method and conditions of payment to be made to the supplier under this contract shall be specified in SCC.
- 16.2. The supplier shall furnish the purchaser with an invoice accompanied by a copy of the delivery note and upon fulfillment of other obligations stipulated in the contract.
- 16.3. Payments shall be made promptly by the purchaser, but in no case later than thirty (30) days after submission of an invoice or claim by the supplier.
- 16.4. Payment will be made in Rand unless otherwise stipulated in SCC.

# 17. Prices

17.1. Prices charged by the supplier for goods delivered and services performed under the contract shall not vary from the prices quoted by the supplier in his bid, with the exception of any price adjustments authorized in SCC or in the purchaser's request for bid validity extension, as the case may be.

### 18. Contract amendments

18.1. No variation in or modification of the terms of the contract shall be made except by written amendment signed by the parties concerned.

### 19. Assignment

19.1. The supplier shall not assign, in whole or in part, its obligations to perform under the contract, except with the purchaser's prior written consent.

### 20. Subcontracts

20.1. The supplier shall notify the purchaser in writing of all subcontracts awarded under this contracts if not already specified in the bid. Such notification, in the original bid or later, shall not relieve the supplier from any liability or obligation under the contract.

### 21. Delays in the supplier's performance

- 21.1. Delivery of the goods and performance of services shall be made by the supplier in accordance with the time schedule prescribed by the purchaser in the contract.
- 21.2. If at any time during performance of the contract, the supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the goods and performance of services, the supplier shall promptly notify the purchaser in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the supplier's notice, the purchaser shall evaluate the situation and may at his discretion extend the supplier's time for performance, with or without the imposition of penalties, in which case the extension shall be ratified by the parties by amendment of contract.
- 21.3. No provision in a contract shall be deemed to prohibit the obtaining of supplies or services from a national department, provincial department, or a local authority.
- 21.4. The right is reserved to procure outside of the contract small quantities or to have minor essential services executed if an emergency arises, the supplier's point of supply is not situated at or near the place where the supplies are required, or the supplier's services are not readily available.





- 21.5. Except as provided under GCC Clause 25, a delay by the supplier in the performance of its delivery obligations shall render the supplier liable to the imposition of penalties, pursuant to GCC Clause 22, unless an extension of time is agreed upon pursuant to GCC Clause 21.2 without the application of penalties.
- 21.6. Upon any delay beyond the delivery period in the case of a supplies contract, the purchaser shall, without canceling the contract, be entitled to purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract and to return any goods delivered later at the supplier's expense and risk, or to cancel the contract and buy such goods as may be required to complete the contract and without prejudice to his other rights, be entitled to claim damages from the supplier.

### 22. Penalties

22.1. Subject to GCC Clause 25, if the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance. The purchaser may also consider termination of the contract pursuant to GCC Clause 23.

# 23. Termination for default

- 23.1. The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:
  - (a) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract, or within any extension thereof granted by the purchaser pursuant to GCC Clause 21.2;
  - (b) if the Supplier fails to perform any other obligation(s) under the contract; or
- (c) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.
   23.2. In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar
- goods, works or services. However, the supplier shall continue performance of the contract to the extent not terminated.

  23.3. Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.
- 23.4. If a purchaser intends imposing a restriction on a supplier or any person associated with the supplier, the supplier will be allowed a time period of not more than fourteen (14) days to provide reasons why the envisaged restriction should not be imposed. Should the supplier fail to respond within the stipulated fourteen (14) days the purchaser may regard the intended penalty as not objected against and may impose it on the supplier.
- 23.5. Any restriction imposed on any person by the Accounting Officer / Authority will, at the discretion of the Accounting Officer / Authority, also be applicable to any other enterprise or any partner, manager, director or other person who wholly or partly exercises or exercised or may exercise control over the enterprise of the first-mentioned person, and with which enterprise or person the first-mentioned person, is or was in the opinion of the Accounting Officer / Authority actively associated.
- 23.6. If a restriction is imposed, the purchaser must, within five (5) working days of such imposition, furnish the National Treasury, with the following information:
  - (i) the name and address of the supplier and / or person restricted by the purchaser;
  - (ii) the date of commencement of the restriction
  - (iii) the period of restriction; and
  - (iv) the reasons for the restriction.
- These details will be loaded in the National Treasury's central database of suppliers or persons prohibited from doing business with the public sector.

  23.7. If a court of law convicts a person of an offence as contemplated in sections 12 or 13 of the Prevention and Combating of Corrupt Activities Act, No. 12 of 2004, the court may also rule that such person's name be endorsed on the Register, the person will be prohibited from doing business with the public sector for a period not less than five years and not more than 10 years. The National Treasury is empowered to determine the period of restriction and each case will be dealt with on its own merits. According to section 32 of the Act the Register must be open to the public. The Register can be perused on the National Treasury website.

# 24. Anti-dumping and countervailing duties and rights

24.1. When, after the date of bid, provisional payments are required, or antidumping or countervailing duties are imposed, or the amount of a provisional payment or anti-dumping or countervailing right is increased in respect of any dumped or subsidized import, the State is not liable for any amount so required or imposed, or for the amount of any such increase. When, after the said date, such a provisional payment is no longer required or any such antidumping or countervailing right is abolished, or where the amount of such provisional payment or any such right is reduced, any such favourable difference shall on demand be paid forthwith by the contractor to the State or the State may deduct such amounts from moneys (if any) which may otherwise be due to the contractor in regard to supplies or services which he delivered or rendered, or is to deliver or render in terms of the contract or any other amount whichmay be due to him.

### 25. Force Maleure

- 25.1. Notwithstanding the provisions of GCC Clauses 22 and 23, the supplier shall not be liable for forfeiture of its performance security, damages, or termination for default if and to the extent that his delay in performance or other failure to perform his obligations under the contract is the result of an event of force majeure.
- 25.2. If a force majeure situation arises, the supplier shall promptly notify the purchaser in writing of such condition and the cause thereof. Unless otherwise directed by the purchaser in writing, the supplier shall continue to perform its obligations under the contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the force majeure event.

# 26. Termination for insolvency

26.1. The purchaser may at any time terminate the contract by giving written notice to the supplier if the supplier becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to the supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the purchaser.

# 27. Settlement of Disputes

27.1. If any dispute or difference of any kind whatsoever arises between the purchaser and the supplier in connection with or arising out of the contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.

# KWAZULU-NATAL PROVINCE

# STANDARD QUOTATION DOCUMENT FOR QUOTATIONS UP TO R1 000 000

- If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the purchaser or the supplier may give notice to the other party of his intention to commence with mediation. No mediation in respect of this matter may be commenced unless such notice is given to the other party.
- 27.3. Should it not be possible to settle a dispute by means of mediation, it may be settled in a South African court of law.
- 27.4. Mediation proceedings shall be conducted in accordance with the rules of procedure specified in the SCC. 27.5.
  - Notwithstanding any reference to mediation and/or court proceedings herein,
    - (a) the parties shall continue to perform their respective obligations under the contract unless they otherwise agree; and
    - (b) the purchaser shall pay the supplier any monies due the supplier.

### 28. Limitation of liability

- Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 6; 28.1.
  - (a) the supplier shall not be liable to the purchaser, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the supplier to pay penalties and/or damages to the purchaser; and
  - (b) the aggregate liability of the supplier to the purchaser, whether under the contract, in tort or otherwise, shall not exceed the total contract price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.

### 29. Governing language

29.1. The contract shall be written in English. All correspondence and other documents pertaining to the contract that is exchanged by the parties shall also be written in English.

### 30. Applicable law

30.1. The contract shall be interpreted in accordance with South African laws, unless otherwise specified in SCC.

### 31.

- Every written acceptance of a bid shall be posted to the supplier concerned by registered or certified mail and any other notice to him shall be posted by ordinary mail to the address furnished in his bid or to the address notified later by him in writing and such posting shall be deemed to be proper service of
- 31.2. The time mentioned in the contract documents for performing any act after such aforesaid notice has been given, shall be reckoned from the date of posting of such notice.

### 32, Taxes and duties

- A foreign supplier shall be entirely responsible for all taxes, stamp duties, license fees, and other such levies imposed outside the purchaser's country.
- 32.2. A local supplier shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted goods to the purchaser.
- 32.3. No contract shall be concluded with any bidder whose tax matters are not in order. Prior to the award of a bid the Department must be in possession of a tax clearance certificate, submitted by the bidder. This certificate must be an original issued by the South African Revenue Services.

### 33. National Industrial Participation (NIP) Programme

The NIP Programme administered by the Department of Trade and Industry shall be applicable to all contracts that are subject to the NIP obligation.

### Prohibition of Restrictive practices 34.

- 34.1. In terms of section 4 (1) (b) (iii) of the Competition Act No. 89 of 1998, as amended, an agreement between, or concerted practice by, firms, or a decision by an association of firms, is prohibited if it is between parties in a horizontal relationship and if a bidder (s) is / are or a contractor(s) was / were involved in collusive bidding (or bid rigging).
- If a bidder(s) or contractor(s), based on reasonable grounds or evidence obtained by the purchaser, has / have engaged in the restrictive practice referred to above, the purchaser may refer the matter to the Competition Commission for investigation and possible imposition of administrative penalties as contemplated in the Competition Act No. 89 of 1998.
- If a bidder(s) or contractor(s), has / have been found guilty by the Competition Commission of the restrictive practice referred to above, the purchaser may, in addition and without prejudice to any other remedy provided for, invalidate the bid(s) for such item(s) offered, and / or terminate the contract in whole or part, and / or restrict the bidder(s) or contractor(s) from conducting business with the public sector for a period not exceeding ten (10) years and / or claim damages from the bidder(s) or contractor(s) concerned.



### SPECIAL CONDITIONS OF CONTRACT

SCC

### 1. AMENDMENT OF CONTRACT

Any amendment to or renunciation of the provisions of the contract shall at all times be done in writing and shall be signed by both parties. 1.1.

### 2. **CHANGE OF ADDRESS**

2.1. Bidders must advise the Department of Health (institution where the offer was submitted) should their address (domicillum citandi et executandi) details change from the time of bidding to the expiry of the contract.

### **GENERAL CONDITIONS ATTACHED TO THIS QUOTATION** 3.

- The Department is under no obligation to accept the lowest or any quote. 3.1.
- The Department reserves the right to communicate in writing with vendors in cases where information is incomplete or where there are obscurities 3.2. regarding technical aspects of the offer, to obtain confirmation of prices or preference claims in cases where it is evident that a typing, written, transfer or unit error has been made, to investigate the vendor's standing and ability to complete the supply/service satisfactorily.
- ALL DECISIONS TAKEN BY THE DEPARTMENT ARE FINAL, INCLUDING THE AWARD OR CANCELLATION OF THIS QUOTATION. 3.3.
- 3.4, The price quoted must include VAT (if VAT vendor).
- Should a bidder become a VAT vendor after award or during the implementation of a contract, they may not request the VAT percentage from the 3.5. Department as the service provider made an offer during the period they were not registered as a VAT vendor. The Department is only liable for any VAT from registered VAT vendors as originally stated on the quotation document.
- The bidder must ensure the correctness & validity of the quotation:
  - (i) that the price(s), rate(s) & preference quoted cover all for the work/item (s) & accept that any mistakes regarding the price (s) & calculations will be at the bidder's risk;
  - (ii) it is the responsibility of the bidder to confirm receipt of their quotation and to keep proof thereof.
- 3.7. The bidder must accept full responsibility for the proper execution & fulfilment of all obligations conditions devolving on under this agreement, as the Principal (s) liable for the due fulfilment of this contract,
- This quotation will be evaluated based on the preferential procurement points system, specification, correctness of information and/or functionality 3.8. criteria. All required documentation must be completed in full and submitted.
- 3.9, Offers must comply strictly with the specification.
- 3.10. Only offers that meet or are greater than the specification will be considered.
- 3.11. Late offers will not be considered.
- Expired product/s will not be accepted. All products supplied must be valid for a minimum period of six months. 3.12.
- 3.13. Used/ second-hand products will not be accepted.
- 3.14. A bidder not registered on the Central Suppliers Database or whose verification has failed will not be considered.
- 3.15. All delivery costs must be included in the quoted price for delivery at the prescribed destination.
- Only firm prices will be accepted. Such prices must remain firm for the contract period. Non-firm prices (including rates of exchange variations) will not be 3.16. 3.17.
- In cases where different delivery points influence the pricing, a separate pricing schedule must be submitted for each delivery point. 3.18.
- In the event of a bidder having multiple quotes, only the cheapest according to specification will be considered. 3.19.
- Verification will be conducted to identify if bidders have multiple companies and are cover-quoting for this bid.
- In such instances, the Department reserves the right to immediately disqualify such bidders as cover-quoting is an offence that represents both 3.20. corruption and acquisition fraud.
- Should there be a variation in price and such variation is above the order amount, the Department will reserve the right to place a new order. 3.21.

The Department reserves the right to negotiate with the shortlisted bidder/s prior or post award. The terms and conditions for negotiations will be 4.1. communicated to the shortlisted bidder/s prior to invitation to negotiations. This will be done to ensure value for money and where the bidder/s price is deemed to be exorbitant, uneconomical or not market related.

# SPECIAL INSTRUCTIONS AND NOTICES TO BIDDERS REGARDING THE COMPLETION OF THIS QUOTATION.

- Unless inconsistent with or expressly indicated otherwise by the context, the singular shall include the plural and vice versa and with words importing the 5.1, masculine gender shall include the feminine and the neuter.
- Under no circumstances whatsoever may the quotation/bid forms be retyped or redrafted. Photocopies of the original bid documentation may be used, but an original signature must appear on such photocopies.
- The bidder is advised to check the number of pages and to satisfy himself that none are missing or duplicated. 5.3.
- Quotations submitted must be complete in all respects. However, where it is identified that information in a bidder's response, which does not affect the 5.4. preference points or price, is incomplete in any respect, the said supplier meets all specification requirements and scores the highest points in terms of preference points and price, the Department reserves the right to request the bidder to complete/ submit such information.
- 5.5. Any alteration made by the bidder must be initialled; failure to do so may render the response invalid.
- 5.6. Use of correcting fluid is prohibited and may render the response invalid.
- 5.7. Quotations will be opened in public as soon as practicable after the closing time of quotation.
- Where practical, prices are made public at the time of opening quotations. 5.8.
- If it is desired to make more than one offer against any individual item, such offers should be given on a photocopy of the page in question. Clear 5.9. indication thereof must be stated on the schedules attached.
- 5.10. The Department is under no obligation to pay suppliers in part for work done if the supplier can no longer for fulfil their obligation.

### SPECIAL INSTRUCTIONS REGARDING HAND DELIVERED QUOTATIONS 6.

Quotation shall be lodged at the address indicated not later than the closing time specified for their receipt, and in accordance with the directives in the 6.1.



- 6.2. Each quotation shall be addressed in accordance with the directives in the quotation documents and shall be lodged in a separate sealed envelope, with the name and address of the bidder, the quotation number and closing date indicated on the envelope. The envelope shall not contain documents relating to any quotation other than that shown on the envelope. If this provision is not complied with, such quotations/bids may be rejected as being invalid.
- 6.3. All quotations received in sealed envelopes with the relevant quotation numbers on the envelopes are kept unopened in safe custody until the closing time of the quotation/bids. Where, however, a quotation is received open, it shall be sealed. If it is received without a quotation/bid number on the envelope, it shall be opened, the quotation number ascertained, the envelope sealed and the quotation number written on the envelope.
- 6.4. A specific box is provided for the receipt of quotations, and no quotation found in any other box or elsewhere subsequent to the closing date and time of quotation will be considered.
- 6.5. Quotation documents must not be included in packages containing samples. Such quotations may be rejected as being invalid.

### 7. SAMPLES

7.2.

- 7.1. In the case of the quote document stipulating that samples are required, the supplier will be informed in due course when samples should be provided to the institution. (This decreases the time of safety and storage risk that may be incurred by the respective institution). The bidders sample will be retained if such bidder wins the contract.
  - (i) If a company/s who has not won the quote requires their samples, they must advise the institution in writing of such.
  - (ii) If samples are not collected within three months of close of quote the institution reserves the right to dispose of them at their discretion.
  - Samples must be made available when requested in writing or if stipulated on the document.
    - If a Bidder fails to provide a sample of their product on offer for scrutiny against the set specification when requested, their offer will be rejected. All
    - (i) testing will be for the account of the bidder.

### 8. COMPULSORY SITE INSPECTION / BRIEFING SESSION

8.1. Bidders who fail to attend the compulsory meeting will be disqualified from the evaluation process.

(i) The ins	titution has determi	ned that a comp	ulsory site meeting Will	not take plac	e.		
(ii) Date:		1	Time:	<u>:</u>	Place:		
Institution Stamp:	,			Institution Site	e Inspection / briefing s	session Official:	
				Full Name:			
				Signature:			
				Date:			

### 9 STATEMENT OF SUPPLIES AND SERVICES

9.1. The contractor shall, when requested to do so, furnish particulars of supplies delivered or services executed. If he/she fails to do so, the Department may, without prejudice to any other rights which it may have, institute inquiries at the expense of the contractor to obtain the required particulars.

# 10. SUBMISSION AND COMPLETION OF SBD 6.1

10.1. Should a bidder wish to qualify for preference points they must complete a SBD 6.1 document. Failure by a bidder to provide all relevant information required, will result in such a bidder not being considered for preference point's allocation. The preferences applicable on the closing date will be utilized. Any changes after the closing date will not be considered for that particular quote.

### 11. TAX COMPLIANCE REQUIREMENTS

- 11.1. In the event that the tax compliance status has failed on CSD, it is the suppliers' responsibility to provide a SARS pin in order for the institution to validate the tax compliance status of the supplier.
- 11.2. In the event that the institution cannot validate the suppliers' tax clearance on SARS as well as the Central Suppliers Database, the quote will not be considered and passed over as non-compliant according to National Treasury Instruction Note 4 (a) 2016/17.

### 12. TAX INVOICE

- 12.1. A tax invoice shall be in the currency of the Republic of South Africa and shall contain the following particulars:
  - (i) the name, address and registration number of the supplier;
  - (ii) the name and address of the recipient;
  - (iii) an individual serialized number and the date upon which the tax invoice
  - (iv) a description and quantity or volume of the goods or services supplied;
  - (v) the official department order number issued to the supplier;
  - (vi) the value of the supply, the amount of tax charged;
  - (vii) the words tax invoice in a prominent place.

### 13. PATENT RIGHTS

13.1. The supplier shall indemnify the KZN Department of Health (hereafter known as the purchaser) against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

### 14. PENALTIES

14.1. If at any time during the contract period, the service provider is unable to perform in a timely manner, the service provider must notify the institution in writing/email of the cause of and the duration of the delay. Upon receipt of the notification, the institution should evaluate the circumstances and, if deemed necessary, the institution may extend the service provider's time for performance.



- 14.2. In the event of delayed performance that extends beyond the delivery period, the institution is entitled to purchase commodities of a similar quantity and quality as a substitution for the outstanding commodities, without terminating the contract, as well as return commodities delivered at a later stage at the service provider's expense.
- 14.3. Alternatively, the institution may elect to terminate the contract and procure the necessary commodities in order to complete the contract. In the event that the contract is terminated the institution may claim damages from the service provider in the form of a penalty. The service provider's performance should be captured on the service provider database in order to determine whether or not the service provider should be awarded any contracts in the future.
- 14.4. If the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance.

### 15. TERMINATION FOR DEFAULT

- 15.1. The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:
  - (i) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract,
  - (ii) if the supplier fails to perform any other obligation(s) under the contract; or
  - (iii) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.
- 15.2. In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar goods, works or services.
- 15.3. Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.
- 16. THE DEPARTMENT RESERVES THE RIGHT TO PASS OVER ANY QUOTATION WHICH FAILS TO COMPLY WITH THE ABOVE.



SBD 6.1.

# PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2022

This preference form must form part of all tenders invited. It contains general information and serves as a claim form for preference points for specific goals.

NB: BEFORE COMPLETING THIS FORM, TENDERERS MUST STUDY THE GENERAL CONDITIONS, DEFINITIONS AND DIRECTIVES APPLICABLE IN RESPECT OF THE TENDER AND PREFERENTIAL PROCUREMENT REGULATIONS, 2022

### 1. GENERAL CONDITIONS

- 1.1. The following preference point systems are applicable to invitations to tender:
  - the 80/20 system for requirements with a Rand value of up to R50 000 000 (all applicable taxes included); and
  - the 90/10 system for requirements with a Rand value above R50 000 000 (all applicable taxes included).
- 1.2. The applicable preference point system for this tender is the 80/20 preference point system.
- 1.3. Points for this tender (even in the case of a tender for income-generating contracts) shall be awarded for:
  - (a) Price; and
  - (b) Specific Goals.
- 1.4. The maximum points for this tender are allocated as follows:

	POINTS
PRICE	80
SPECIFIC GOALS	20
Total points for Price and Specific Goals	100

- 1.5. Failure on the part of a tenderer to submit proof or documentation required in terms of this tender to claim points for specific goals with the tender, will be interpreted to mean that preference points for specific goals are not claimed.
- 1.6. The organ of state reserves the right to require of a tenderer, either before a tender is adjudicated or at any time subsequently, to substantiate any claim in regard to preferences, in any manner required by the organ of state.

# 2. DEFINITIONS


- (a) "tender" means a written offer in the form determined by an organ of state in response to an invitation to provide goods or services through price quotations, competitive tendering process or any other method envisaged in legislation;
- (b) "price" means an amount of money tendered for goods or services, and includes all applicable taxes less all unconditional discounts;
- (c) "rand value" means the total estimated value of a contract in Rand, calculated at the time of bid invitation, and includes all applicable taxes;
- (d) "tender for income-generating contracts" means a written offer in the form determined by an organ of state in response to an invitation for the origination of income-generating contracts through any method envisaged in legislation that will result in a legal agreement between the organ of state and a third party that produces revenue for the organ of state, and includes, but is not limited to, leasing and disposal of assets and concession contracts, excluding direct sales and disposal of assets through public auctions; and
- (e) "the Act" means the Preferential Procurement Policy Framework Act, 2000 (Act No. 5 of 2000).

# 3. FORMULAE FOR PROCUREMENT OF GOODS AND SERVICES


### 3.1. POINTS AWARDED FOR PRICE

### 3.1.1. THE 80/20 OR 90/10 PREFERENCE POINT SYSTEMS

A maximum of 80 or 90 points is allocated for price on the following basis:



OR



### Where

Pt

Ps = Points scored for price of tender under consideration


= Price of tender under consideration

Pmin = Price of lowest acceptable tender

# 3.2. FORMULAE FOR DISPOSAL OR LEASING OF STATE ASSETS AND INCOME GENERATING PROCUREMENT

### 3.2.1. POINTS AWARDED FOR PRICE

A maximum of 80 or 90 points is allocated for price on the following basis:



### Where

Ps = Points scored for price of tender under consideration

Pt = Price of tender under consideration Pmax = Price of highest acceptable tender

### STANDARD QUOTATION DOCUMENT FOR QUOTATIONS UP TO R1 000 000



### 4. POINTS AWARDED FOR SPECIFIC GOALS

- 4.1. In terms of Regulation 4(2); 5(2); 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded for specific goals stated in the tender. For the purposes of this tender the tenderer will be allocated points based on the goals stated in table 1 below as may be supported by proof/ documentation stated in the conditions of this tender:
- 4.2. In cases where organs of state intend to use Regulation 3(2) of the Regulations, which states that, if it is unclear whether the 80/20 or 90/10 preference point system applies, an organ of state must, in the tender documents, stipulate in the case of—
  - (a) an invitation for tender for income-generating contracts, that either the 80/20 or 90/10 preference point system will apply and that the highest acceptable tender will be used to determine the applicable preference point system; or
  - (b) any other invitation for tender, that either the 80/20 or 90/10 preference point system will apply and that the lowest acceptable tender will be used to determine the applicable preference point system,

then the organ of state must indicate the points allocated for specific goals for both the 90/10 and 80/20 preference point system.

Table 1: Specific goals for the tender and points claimed are indicated per the table below.

Note to tenderers: The <u>tenderer</u> must indicate <u>how</u> they claim points for each preference point system.

Fr. over	
	Number of points   Number of points   Number of points   Points   Number of points   Nu
RDI	P Goal: Full points allocated to promote enterprises owned by Youth
	DECLARATION WITH REGARD TO COMPANY/FIRM
4.3.	Name of company/firm:
4.4.	Company registration number:
4.5.	TYPE OF COMPANY/ FIRM [tick applicable box]  Partnership/Joint Venture / Consortium  One-person business/sole propriety  Close corporation  Public Company  Personal Liability Company  (Pty) Limited  Non-Profit Company  State Owned Company
4.6.	I, the undersigned, who is duly authorised to do so on behalf of the company/firm, certify that the points claimed, based on the specific goals as advised in the tender, qualifies the company/ firm for the preference(s) shown and I acknowledge that:  i) The information furnished is true and correct;  ii) The preference points claimed are in accordance with the General Conditions as indicated in paragraph 1 of this form;  iii) In the event of a contract being awarded as a result of points claimed as shown in paragraphs 1.4 and 4.2, the contractor may be required to furnish documentary proof to the satisfaction of the organ of state that the claims are correct;  iv) If the specific goals have been claimed or obtained on a fraudulent basis or any of the conditions of contract have not been fulfilled, the organ of state may, in addition to any other remedy it may have —  (a) disqualify the person from the tendering process;  (b) recover costs, losses or damages it has incurred or suffered as a result of that person's conduct;  (c) cancel the contract and claim any damages which it has suffered as a result of having to make less favourable arrangements due to such cancellation;  (d) recommend that the tenderer or contractor, its shareholders and directors, or only the shareholders and directors who acted on a fraudulent basis, be restricted from obtaining business from any organ of state for a period not exceeding 10 years, after the audi alteram partern (hear the other side) rule has been applied; and  (e) forward the matter for criminal prosecution, if deemed necessary.
	SIGNATURE(S) OF TENDERER(S)  SURNAME AND NAME:  DATE:  ADDRESS:




NAME OF PR	COCURING	KZN DE	PARTMENT OF HEALTH CENTRAL CO	M. ON BELLALE OF		
FACILITY		KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF OF KING CETSHWAYO DISTRICT OFFICE				
ITEM DESCR	RIPTION	BAROM	ROMETER			
ITEM PURPO			or the progress against targets			
		10 mont	or the progress against targets			
		i				
NAME OF TH	IE BIDDER	1				
ITEM DETAIL	ED SPECIFICAT	TION (INCL	UDE SIZE, COLOUR AND MATERIAL	COMPLIES (YES/NO)		
EIC			,			
1.	Barometer					
2.	Poster					
<u> </u>				-		
3.	Paper: 250gsm					
4.	Tauting a and Ol					
<b>4.</b>	lexting and Sr	iading: poi	rtrait printed 4 process colours front only			
5.	Size: A1					
<b>)</b>	OIZE. AT					
6.	Laminated Glos	s only side	only			
		o offiny orac	Offiny			
QUALITY STA	NDARD					
UNIT OF MEA	SURE OR PACK	AGING	unit			
I.E. (UNIT/BO)	X/ROLL/PACK/B	AIL				
ETC)						
SAMPLE REQUIRED YES		YES				
(YES/NO) IF YES WHEN AND HOW?						
ADDENDUM T	-		· · · · · · · · · · · · · · · · · · ·			
	אַר		Not applicable			
ATTACHED (YES OR NO)				1		
(TES OR)	NO)					

# Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work

Name of End-user (in full)  Designation / Rank (in	Manie V Whosh	
full) Signature	A thirthen il	Designation/ Rank (in full)
Date	Way	Signature
Date	304/10/11	Date 11/10/2024





NAME	OF	KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF OF						
	<b>PROCURING</b>	KING CETSHWAYO DISTRICT OFFICE						
FACILI	ITY							
ITEM C	DESCRIPTION	CHART VIRAL LOAD MONITORING FOR CLIENTS ON TLD						
ITEM P	PURPOSE	Designed for outlining viral load monitoring for clie	Designed for outlining viral load manifesing for all and					
	OI WOOL	besigned for outlining viral load monitoring for cile	ents.					
NAME	OF THE							
BIDDE		·						
ויייייייייייייייייייייייייייייייייייייי	1							
ITEM	ETAIL ED CDEC	DECATION (INCLUDE OUTE COLOUR AND	T					
MATE	RIAL ETC	IFICATION (INCLUDE SIZE, COLOUR AND	COMPLIES (YES/NO)					
1.	Poster							
•	5 (0)							
2.	Paper : (Calend	ar type) Gloss 320gsm						
3.	Texting and Shading: Landscape printed to 1 side.							
4.	. Colour : Full colour							
5.	Size : A3							
QUALIT	TY STANDARD							
	F MEASURE OF	R unit						
PACKA	GING I.E.							
(UNIT/B	OX/ROLL/PACI	K/BAIL						
ETC)								
SAMPL	E	YES						
REQUIRED								
(YES/NO)								
IF YES WHEN AND								
HOW?								
	DUM TO							
	ICATION	Not applicable						
ATTAC		Hot applicable						
	S OR NO)							

# Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work



Name of End-user (in full)	Manua V Mkhabele	Name of SCM Rep (in full)	NNHAMORED
Designation / Rank (in full)	Dutational	Designation/ Rank (in full)	SC _
Signature (	My ar	Signature	@ (CO)
Date	2024/10/11	Date	2024/10/17

Routine VI. monitoring for virally suppressed cirents as outlined in the algorithm Routine HIV VL Monitoring on ART" on page 18

VL < 50 c/mL

VEunsuppressed (VL≥50 c/ml) (This includes previous VL level of 50-999 and VL > 1000 c/ml)



Do a thorough assessment of the cause of an elevated VL. Consider the possibility of:

- A. Adherence problems (see "Enhanced Adherence Support" on page 20)
- B. Bugs (Intercurrent Infections)
- C. In-Correct ART dosage (see Annexure 5 "Drug Dosing Chart" on page 34)
- D. Drug Interactions (see "Drug Interactions with DTG and Rifampicin-containing TB Treatment" on page 13)
- E. REsistance (if > 2 years on treatment)

Implement interventions to re-suppress the VL, including Enhanced Adherence Support if indicated (See Annexure 3 Enhanced Adherence Counselling). Recommend condom use and contraception as appropriate

Repeat VL after 3 months

Repeat VI, unsuppressed -{VL > 50 c/ml}




Re-assess and resolve adherence issues! 2

(See "ABCDE assessment of an Elevated Viral Load" on page 20 and Annexure 3 "Enhanced Adherence Support" on page 20)

On TLD for at least 2 years

On TLD less than 2 years 3



Go to the algorithm for "Management of Confirmed Virological Failure on TID: on page 21

If adherence still suboptimal 4, or persistent low-level viraemia (2 or more consecutive VLs between 50 and 999 c/mL)

Repeat VL at next scheduled routine VL (i.e., in 6 months' time) Intensify efforts to resolve adherence issues 2

- Due to their high genetic barrier, resistance to a first-line DTG-containing (TLD1) regimen is extremely rare. If other reasons for an unsuppressed VL have been addressed or excluded, e.g., drug interactions, and the client remains unsuppressed at their repeat VL, suboptimal adherence remains the most probable cause for non-suppression. The highest probability of improving adherence would be to remain on a once-daily, well-tolerated, fixed-dose combination regimen (TLD) while identifying and addressing the underlying root causes of non-adherence. 99,9% of these clients will re-suppress on TLD if adherent
- Repeat ABCDE assessment as outlined on "ABCDE assessment of an Elevated Viral Load" on page 20. Remember to ask about treatment side-effects, the potential cost of transport or loss of Income related to clinic visits, non-disclosure, gender-based violence (GBV), and current or prior drug interactions. Current or previous drug interactions with rifampicin, carbamazepine, phenytoin, phenobarbital, or the polyvalent cations may have resulted in the development of resistance.
- Drug interactions may also warrant an expert discussion and authorisation of a resistance test earlier than 2 years on the regimen. If necessary, discuss with an expert
- Objective measures of good adherence include at least one of:
  - Pharmacy refills > 80% in the last 6-12 months (if this is known)
  - Attendance of > 80% of scheduled clinic visits in the last 6-12 months (if this is known)
  - Detection of current antiretroviral drug/s in the client's blood or urine, if available

Note: Self-reported adherence is not considered a measure of good adherence!

ART, Antiretroviral therapy; DTG, Dolutegravir; LLV, Low-level viraemia; SOP, Standard operating procedure; TL, Third-line; TLD, fixed-dose combination of tenofovir, lamivudine, DTG; VL, Viral load.




NAME		KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF OF						
	PROCURING	KING CETSHWAYO DISTRICT OFFICE						
FACIL								
ITEM D	DESCRIPTION	CHARTS-SWITCHING CHILDREN ON PI CONTAINING REGIMEN						
ITEM F	PURPOSE	To provide a structured guide for clinicians						
		guido foi officialis						
		1						
NAME	OF THE							
BIDDE								
ITEM	ETAIL ED ODEC	IFICATION (INCLUDE OFFE COLOUR AND						
MATE	RIAL ETC	IFICATION (INCLUDE SIZE, COLOUR AND	COMPLIES (YES/NO)					
1.	Poster							
2.	Paper : (Calend	ar type) Gloss 320gsm						
3.	Texting and Sha	ading: Landscape printed to 1 side.						
4.	Colour: Full col	our						
5.	Size: A3 post							
QUALI	TY STANDARD		<u> </u>					
4								
LINITO	F MEASURE OF	unit						
	GING I.E.	\ uiiit						
		Z/DAU						
	BOX/ROLL/PAC	VBAIL						
ETC)	F	Vice I						
SAMPL		YES	***					
REQUIR								
(YES/N		AND						
	YES WHEN AND							
HOW?								
	DUM TO							
	ICATION	Not applicable						
ATTACI		• •						
<u>(YE</u>	S OR NO)							
		· · · · · · · · · · · · · · · · · · ·						

# Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
- 3. Other Professional Services may have additional Terms of Reference or Scope of Work

Name of End-user (in full)	Marion V Wharle	Name of SCM Rep (in full)	OF AM IN INCOME
Designation / Rank (in full)	Nutrithansb	Designation/ Rank (in full)	806
Signature	Wen-	Signature	W to ver
Date	zorthali	Date	20-24/0/11



If the most recent VL before their regimen change was  $\geq 50$  c/mL, repeat VL 3 months after starting the new regimen to confirm viral re-suppression

- 1. Although objective measures of poor adherence include pharmacy refills or attendance of scheduled clinic visits in the previous 6-12 months of <80%, adherence difficulties in young children are often linked to poor tolerability of unpalatable formulations, particularly LPV/r solution. It is important to ask the caregiver about how the child tolerates the medication e.g., does the child refuse to swallow the medicine or spit out or vomit the medicine, and whether the caregiver has been able to overcome this. Considering these limitations, objective measures of good adherence could include one of the following:</p>
  - a. Pharmacy refills > 80% in the last 6-12 months (if this is known)
  - Attendance of > 80% of scheduled clinic visits in the last 6-12 months (if this is known)
  - Detection of current antiretroviral drug/s in the client's blood or urine, if available
- 2. If a switch to the 4-in1 capsules does not improve adherence, or is not available, continue to switch to ABC + 3TC + DTG as for non-adherent children on LPV/r tablets
- 3. The following would qualify as HIV experts: the HIV Helplines, a paediatric infectious disease specialist or the paediatric Third line ART committee



NAME		KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF OF							
	PROCURING	KING CETSHWAYO DISTRICT OFFICE							
FACILI									
	M DESCRIPTION ART DRUG DOSING CHART FOR CHILDREN 2022								
ITEMP	URPOSE	Designed to	reduce the viral load in the blood.						
NAME	OF THE								
BIDDE									
D.DDE.									
ITEM D	ETAILED SPEC	IFICATION	(INCLUDE SIZE, COLOUR AND	COMPLIES (YES/NO)					
MATER	RIAL ETC		(INCLODE CIZE, COLOON AND	COMPLIES (TES/NO)					
1.	Poster								
				·					
2.	Paper : (Calend	ar type) Glo	ss 320gsm						
3.	Texting and Shading: Landscape printed to 1 side.								
4.	Colour : Full colour								
5.	Size : A3 post	· · · · · · · · · · · · · · · · · · ·							
<b>U.</b>	0.20 . 713 post								
QUALIT	Y STANDARD		· · · · · · · · · · · · · · · · · · ·						
				İ					
	F MEASURE OF	₹	unit						
	GING I.E.								
	OX/ROLL/PAC	K/BAIL							
ETC)		V50							
SAMPLI		YES							
(YES/NO									
	WHEN AND								
HOW?									
ADDEN	DUM TO								
	ICATION		Not applicable						
ATTACH	· · ·		, , , , , , , , , , , , , , , , , , , ,						
(YE	S OR NO)								

# Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work

Name of End-user (in full)	Mans V Michalele	Name of SCM Rep (in full)	UN MUDICO
Designation / Rank (in full)	Natotsonish	Designation/ Rank (in full)	SCE
Signature	(War	Signature	(Dec)
Date	13024/10/11	Date	3000011



# ANTIRETROVIRAL DRUG DOSING CHART FOR CHILDREN 2022 Compiled by Child and Adolescent Committee of SA HIV Clinicians Society in collaboration with the Department of Health

		Target dose	Avallable formula- tions		Wt. (kg) 3 - 5.9	6.9.9		10 · 13.9	14 - 19.9	20 - 24.9	25 - 29.9	30 - 39.9	94
	Efavirenz (EFV)	By weight band	Caps/tabs 50, 200, 600 mg, FDC TEE 300/200/600 mg, TABLETS MUST BE	WHOLE	ţ	necom-		1 x 200 mg cap/tab nocte	1 x 200 mg cap/fab +	caps/tabs nocte	2 x 200 mg caps/tabs nocte		2 x 200 mg caps/tabs nocte QR PDC: TEE II
	# Atazanavir (ATV) + Ritonavir	By weight band ONCE daily	ATV caps 150, 200 mg; RTV tabs 100 mg; RTV tabs 100 mg; 300/100 mg RTV TABLETS AND ATV/ FDC TABLETS	MUST BE SWALLOWED WHOLE		Not recommended			ATV 1 x 200 mg cap od + RTV 1 x 100 mg tab or 100 mg oral powder (1 packet) od	Million de la referencia por esta por e	RTV ig FDC		RTV 1 x 100 mg tab or 100 mg oral powder (1 packet) od
v Î	Lopinavir/ritonavir when on rifampicin (and for 2 weeks after stopping tifampicin)	LPV/r std dose + Dodble-dose LPV/r std dose + Dodble-dose LPV/r stger-boosting IOR tabs ONLy if with ritonavit (RIV) able to swallow powder PWICE daily whole LPV/r tabs (20.75xLPV dose boil   TWICE daily	Adult tabs 200/50 mg. Peed tabs 100/25 mg		Do not use	double-dose		3x 100/25 mg paed tabs bd	4 x 100/25 mg paed tabs bd no	Zx 200/50 mg adult tabs bd	6 x 100/25 mg paed tabs bd OR 3 x 200/50 mg adult tabs bd	% 8 x 100/25 mg	paed tabs bd OR 4 x 200/50 mg adult tabs bd
saith	Lopinavir/rito rifampicin (ar after stoppir	LPV/r std doze + super-boosting   E with ritonavir (RTV) powder TWICE dally (≥0.75xLPV dose bd)	Oral powder 100 mg/packet	ahina / Olor	LPV/r std dose (see purple	RTV powder 100 mg (1 packer) bd		LPV// startbse	(see purple column) + oral: RTV powder 200 mg (2 packets) bd		LPV/r std dose (see purple	column) + oral RTV powder	300 mg (3 packets) bd
ne pepartment of neath	Abacavir + Lamivudine + Lopinavir/ ritonavir	By weight band TWICE daily	Caps 30/15/40/10 mg IF PATIENT IS ON RIFAMPIGIN TB TREATMENT, ADD RTV POWDER (PRST CONTINUE)	e) and infante wei	2 capsules bd	3 capsules bd	*	4 capsules bd	5 capsules bd	6 capsules bd		Not recommended	nainean de la lacente de l
	Lopinavir/ritonavir (LPV/fr)	3007/5 mg/mz/dose LPV/f	Additubles 200/20 mg/ml Additubles 200/50 mg/ml Fallers Muss Be NARLOWED WHOLE Folder Ag 10 mg are carsus: OWY FOR LISE R NOT TO ARRAING BEY FOR LISE R NOT TO ARRAING BEY FOR LISE R NOT TO ARRAING BEY FOR LISE R NOT FOR	Consult with a clinician experienced in paediatric ARV prescribing for neonates (< 28 days of apel and infants weighting < 25%	* Lmf bd OR	* <u>1.5 ml bá o</u> R 3 capsules bd	2 mi bá OR	4 Capsules bd OR 2 X 100/25 mg paed tabs am + 1 X 100/25 mg paed tab pm	2.5 mibd OR 5 capcules bd OR 2 x 100/25 mg paed tabs bd OR 1 x 200/50 mg adujt tab bd	a mi bd OR 6 capsules bd OR 2 x 100/25 mg peed tabs bd OR 1 x 200/50 mg adult rab bd	3.5 m bd oR 7 capsules bd oR 3.x 100/25 mg paed tabs bd OR 1x200/90 mg adult tab bd + 1.x 100/25 mg paed tab bd	5 mibd OK	10 capsules bd OR 4x400/25 mg pared tabs bd OR 2x200/50 mg adult tabs 5d
	Dolutegravir when on Rifampicin	By weight band TWICE DAILY	Dispersible tabs (DT) 10 mg. Film coated (EC) tabs 50 mg. FOC. Tab 300/300/50 mg. ABG/31C/DTS 600/300/50 mg. DT AND EC/DELIFS ARE NOT BIOGRADIA/ALENT	in paediatric ARV prescri	0.5 x 10 mg DT bd	1.5 x 10 mg DT bd		2×10 mg DT bd	2.5 x 10 mg DT bd		9	1 x 50 mg FC tab bd  OR FDC: TLD if eligible  od + 50 mg DTG FC tab	12 hours later OR FDC: ABC/3TC/ DTG if eligible od + 50 mg DTG FC tab 12 hours later
	Dolutegravir (DTG)	by weight land Owic fally	Dispensive table (97) 10 mg. Film coarset (17) table 50 mg. ABC TC (10) 200 COARSE (18) DI ARD FC TABLETS ARE FOLL	n a clinician experienced	05x10mg DJ od **	1.5 x 10 mg DT od	e Pare Level	2×10 mg prod	25x10m, und	3 x 10 mg DT od ON 1 x 50 mg r C tab od	1×50mg Crangel Off. FDC: ABC/3TL/D[G)F eligible off.	mg Potential Of	EDC. NO. 1 S. 1
	Zidovudine (AZT)	180-240 mg/m2/dose TWICE daily	Sol. 10 mg/ml, Tabs 100, 300 mg (not scored), FDC; AZT/STC 300/150 mg	Consult wit	6 ml bd	9 ml bd	12 ml bd	1 x 100 mg tabs bd	2 x 100 mg tabs am + 1 x 100 mg tab pm OR 15 ml bd	2 x 100 mg tabs bd OR 20 ml bd	1 x 300 mg tab bd	OR 1×AZT/3TC 300/150 mg	tab bd
	Lamivudine (3TC)	4 mg/kg/dose TWICE daily OR If ≥ 10kg: 8 mg/kg/dose ONCE daily	Sol. 10 mg/mi Tabs 150 mg (scored)		3 m bd	4 ml bd	Once daily dosing > 10 kg	12 ml od	1 x 150 mg tab od	Antalia	2 x 150 mg tabs od		
	Abacavir (ABC)	Empligation Three align Three align ORTE LONG TEMPLATOR ONCE Sally	Solution of the condition of the conditi		3mlod on the following tabled	4 ml bb OR 1.5 x 60 mg tab bo	Once daily Control of Control Control of Control	d s forme rabs od	S×60 mg tabs od Om 1×300 mg tab od	1x 300 mg tab + 1x 500 mg tab + 1x 50 mg tab od od on tab od on tab od		A Suming	
		Target	Available formula- tions	MR. (%g)	3.5.9	6-9.9	,	7	14 - 19.9	20 - 24.9	25 - 29.9		× 40



NAME	OF	KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF OF							
	PROCURING	KING CETSHWAYO DISTRICT OFFICE							
FACILI		TOTAL OF TOTAL OF DISTRICT OFFICE							
	DESCRIPTION	CHART S-MANAGEMENT OF CONFIRMED VL FAILURE ON TLD							
		CHART S	MANAGEMENT OF CO	NFIRMED VL F	AILURE ON TLD				
I ITEM P	PURPOSE	Designed 1	or outlining the managem	nent of confirm	ed VL failure				
1									
NAME	OF THE								
BIDDE	R								
ITEM D	FTAIL ED SDEC	TEICATION	(INCLUDE SIZE, COLO	LID AND					
MATE	RIAL ETC	JIFICATION	(INCLUDE SIZE, COLO	UR AND	COMPLIES (YES/NO)				
1.	Poster								
1.	Poster								
2.	Paper : (Calend	lar type) Gl	oss 320gsm						
3.	Texting and Sha	ading: Land	scape printed to 1 side.						
		J							
4.	. Colour : Full colour								
5.	Size : A3 poster	•							
ļ <b>.</b>	Oizo . Mo poster								
OLIAL IT	TY STANDARD	<u> </u>	-						
QUALIT	I I STANDARD								
				ļ					
	F MEASURE OF	₹	unit		-				
	GING I.E.								
	BOX/ROLL/PAC	K/BAIL							
ETC)					·				
SAMPL	E	YES							
REQUIF	RED								
(YES/NO)									
	WHEN AND								
HOW?									
	DUM TO								
	CATION								
			Not	applicable					
ATTACI									
(YE	S OR NO)								


# Note:

- 1. Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
- Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work

Name of End-user (in full)  Designation / Rank (in	Manin V Michalde	
full) Signature	Datakourd	Designation/ Rank (in full)
Date	Man	Signature Qui
Date	13034/10/11	Date Dozq COII

# Management of Confirmed Virological Failure on TLD

(also applicable to ALD and other DTG-containing regimens)



- Objective measures of good adherence include at least one of:
  - Pharmacy refills > 80% in the last 6-12 months (if this is known)
  - Attendance of > 80% of scheduled clinic visits in the last 6-12 months (if this is known)
  - Detection of current antiretroviral drug/s in the client's blood or urine, if available
- Note: Self-reported adherence is not considered a measure of good adherence!
- 2. Due to their high genetic barrier, resistance to a first-line DTG-containing regimen (TLD1) is extremely rare. If other reasons for an unsuppressed VL have been addressed or excluded, e.g., drug interactions and the client remains unsuppressed at their repeat VL, suboptimal adherence remains the most probable cause for non-suppression. The highest probability of improving adherence would be to remain on a once-daily, well-tolerated, fixed-dose combination regimen (TLD) while identifying and addressing the underlying root causes of non-adherence. 99,9% of these clients will re-suppress on TLD if adherent!
- Repeat the ABCDE assessment as outlined on "ABCDE assessment of an Elevated Viral Load" on page 20. Remember to ask about treatment
  side-effects, the potential cost of transport or loss of income related to clinic visits, mental health conditions, non-disclosure, poor social support, or
  substance abuse. If necessary, discuss with an expert or refer to other multidisciplinary team members, if available.
- 4. Special circumstances that may warrant a resistance test for clients on TLD1 include;
  - Incorrect classification as TLD1 (clients who declare themselves as never having had ART before, but who have actually been exposed to ART and may
    have failed a regimen in the past)
  - Perinatally infected adolescents: Unless a clearly documented drug history is available, perinatally infected adolescents should be classified as TLD2
    due to the high likelihood of ART exposure and virological failure in the past
  - Current or previous drug interactions with rifampicin, carbamazepine, phenytoin, phenobarbital, or the polyvalent cations may have resulted in the
    development of resistance. Drug interactions may also warrant an expert discussion and authorisation of a resistance test earlier than 2 years on the
    regimen.

In these types of exceptional circumstances, TLD1 clients with persistent virological failure despite confirmed good adherence may be discussed with an expert to authorise a resistance test on a case-by-case basis.

5. For advice from an HIV expert, approach an HIV Hotline, an infectious disease specialist, or the Third Line ART committee



If in doubt about any aspect of viral load management or switching to second-line, contact one of the following resources:

National HIV & TB Health Care Worker Hotline: 0800 212 506

Right to Care Paediatric, Adolescent and Adult HIV Helpline: 082 352 6642

KZN Paediatric Hotline: 0800 006 603





NAME OF KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF KING CETSHWAYO DISTRICT OFFICE  FACILITY  ITEM DESCRIPTION RE-INITIATING ART IN NON-PREGNANT CLIENTS									
ITEM DESCRIPTION RE-INITIATING ART IN MON DRECMANT OF JENTO									
ITEM PURPOSE To achieve and maintain viral suppression									
NAME OF THE									
BIDDER									
ITEM DETAILED SPECIFICATION (INCLUDE SIZE, COLOUR AND COMPLIES (YES	/NO)								
MATERIAL ETC	,								
1. Poster									
	•								
2. Paper : (Calendar type) Gloss 320gsm									
3. Texting and Shading: Landscape printed to 1 side.									
4. Colour : Full colour									
5. Size : A3 poster	·								
QUALITY STANDARD									
UNIT OF MEASURE OR unit									
PACKAGING I.E.									
(UNIT/BOX/ROLL/PACK/BAIL									
ETC)									
SAMPLE YES									
REQUIRED									
NO)									
YES WHEN AND									
HOW?									
ADDENDUM TO									
SPECIFICATION Not applicable									
ATTACHED									
(YES OR NO)									

# Note:

- 1. Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
- Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work

Name of End-user (in full)  Designation / Rank (in	Ma	nde V	Whatele	Name of SCM Rep (in full)	
full) Signature	Hod	nt bu	11/	Designation/ Rank (in full)	ecc
Date				Signature	Report
Date	Son	10/11		Date	908410111








NAME	OF	KZN DEPARTMENT OF LICALTH OFNEDAL O	014					
1	PROCURING	KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF						
FACILITY		OF KING CETSHWAYO DISTRICT OFFICE						
	SCRIPTION	OUA DEC. MISSAN AND AND AND AND AND AND AND AND AND A						
		CHARTS - VIRAL LOAD COMPLETION & SUP	PRESSION					
ITEM PU	RPOSE	Ensuring the effectiveness of ART & improving over	erall Health					
		and the state of t	ran ricanii					
			•					
NAME O	F THE BIDDER							
		, ·						
ITEM DE	TAU ED ODEOU							
ILEM DE	I AILED SPECIF	FICATION (INCLUDE SIZE, COLOUR AND	COMPLIES					
MAIERIA	ALEIC	·	(YES/NO)					
1.	Poster		1,13,113					
2.	Paper: (Calend	dar type) Gloss 320gsm						
_		131 13pc/ 01033 020gs/11						
3.	Teyting and	Shadings no trait mist at 4						
<b>.</b>	and and a	Shading: portrait printed 4 process colours front						
	only :							
	-							
4.	Size: A2							
QUALITY	STANDARD							
		ļ						
			. i					
UNIT OF	MEASURE OR	UNIT						
PACKAGI		INII						
(UNITAD)	X/ROLL/PACK/	BAIL						
ETC)			·					
SAMPLE		YES						
REQUIRED		·						
(YES/NO)								
IF YES WI	HEN AND		ļ					
HOW?			1					
ADDENDL	JM TO							
SPECIFIC		Not and the						
ATTACHE		Not applicable	1					
	_							
(1ES	OR NO)							
		-						

# Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
- 3. Other Professional Services may have additional Terms of Reference or Scope of Work

SPECIFICATION APPROVED BY							
Name of End-user (in full)	Maryn Mchable	Name of SCM Rep (in full)	NN 181400				
Designation / Rank (in full)	Dutotomich	Designation/ Rank (in full)	800				
Signature	(Wax	Signature	000				
Date	2024 10 11	Date	2024/10/11				



Completion

6 months 12 months

# Fill in the Annual Target and the Month

- •Calculate the monthly target, considering the appointments that were rescheduled for defaulters and appointments scheduled out of Cohort
- •Retrieve the 6 Month Viral load due report from Tier.net.
- •Determine the number of Viral load due appointments due for the week.
- •Fill in the weekly target on the left.
- •Record the actual number of Viral loads done from the number of due on the Viral load report on the right.

# Determine the reason for VL not done:

- •Defaulters add the number appointments for defaulters that was rescheduled to the specific week's target.
- Deduct the number of appointments that were out of cohort for the review period and add the number to the viral load due report of that specific cohort month.

Supprembon

6 months 12 months

### Fill in the annual target and the month

•Obtain the number of 6 Month Viral loads done for the week from Tier.net using Lab track/hardcopies from the Lab or retrieve the Viral load results report from Tier.net to obtain Viral load results for the week.

Fill in the number of Viral loads done to the left.

- •From the Viral load results received record the number of Viral loads that were suppressed to the right.
- •Calculate the monthly target, considering the number of unsuppressed viral loads that was actioned and number of Viral loads repeated.
- •The Viral load result TAT will play a vital role in the weekly performance and should be considered for the review periodFill in the annual target and the month




## **ANNEXURE A: SPECIFICATION FORM**

NAME O	F	KZN DEPARTMENT OF HEALTH CENTRAL SCM - ON BEHALF										
PI	ROCURING	OF KING CETSHWAYO DISTRICT OFFICE	İ									
FACILITY												
		ADULT CLINICAL CHARTS										
ITEM PUR	POSE	<ol> <li>To motivate patient to optimize or prevent illnesses and management.</li> </ol>	ge									
		chronic condition										
	THE DIDDED											
NAME OF	THE BIDDER											
ITEM DET	AII ED CDECIEI	CATION (INCLUDE SIZE, COLOUR AND COMPLIES										
MATERIA		(YES/NO)										
1.	Cover											
	160 GSM white	popor (A4)										
2.	160 GSW WHILE	paper (A4)										
3.	Print on cover:	coat of arms (KZN DOH logo) - color										
4.	Print on cover:	document title(black ink)										
	Content											
		2000 (AA)										
5.	80 GSM white p	paper (A4)										
6.	40 pages printe	d back to back (black ink)										
J.	lo pages prints											
7.	Pages stapled t	o cover (manuscript style)										
QUALITY	STANDARD											
	MEASURE OR	UNIT										
PACKAGI												
	X/ROLL/PACK/	BAIL										
ETC)		YES										
SAMPLE REQUIRE	:n	LE2										
(YES/NO)												
IF YES W	HEN AND											
HOW?												
ADDEND												
SPECIFIC		Not applicable										
ATTACHE												
(YES	OR NO)											

#### Note:

- Health Technology Service (HTS) may have additional Terms of Reference or Scope of Work
   Facility Maintenance may have additional Terms of Reference or Scope of Work
   Other Professional Services may have additional Terms of Reference or Scope of Work

	SPECIFICATION	APPROVED BY	
Name of End-user (in full)	Manin () Mkhasle	1	Bure my 190180
Designation / Rank (in full)	Astribaist	Designation/Rank (in full)	8.0
Signature	( au	Signature	they.
Date	2021/10/24	Date	11/10/20





# **FILE NUMBER**

# **PATIENT NAME**

HAST
ADULT CLINICAL CHART

Referral	clinic:	•			1		Current Clinic:		
1.PATIEN	NT DETA	AILS		į			Deter		
// Firstina	ne			<del></del> '			Date:		<del>_</del>
L Suma			1		Sex:	M / F	Priorie#		
i D Num	The same of		·/.		Jex.	IVI / F	I Address ▼		
Next of kin						<del></del>			
2.LONG-	TERM	RECOE	מא		Use this section	n to maintain an ongoin	g summary of your patient's health. If a to ascertain major features of the clini	nother clinician sees this patie	nt for the first time five
Year HIV	ı mi vivi i	12001			ART start o	ates	to ascertain major features of the clini	Tranfersh	/ /
Diagnoset		if	NOTE:Peti there is prior treat	and the second of the	at this or transferring	clinic	from date of the original start. ew patient with prior HAART exposure		
HAART prior to ab	ove start date?	i		/ HAART / PEP	Dotoile				
Past medical h	istory	Record	here signif	icant medical e	vents that occur	red before this p	patient record was started	d	
				:					
Longitudinal	<b>इ</b> ट्य		Commit	of a call time they		fining the same			
Record Date		Reco.	rd here the d	late and duration of Viral load	on ART in months "  CD4	(b)" (if applicable)	/ CD4 or viral load , regimen o CD4 ,viral load ,stage, pap,re	gimen changes and ho	spitalisations
///	1	Stage	VVeignt	Vitalioau	1 .	Stage de	ining illness, regimen cha	nge , nospitalisation	details , pap , ect.
11									
11									
//									
11									
	ļ							THE RESERVE OF THE PERSON OF T	
							The second secon		
11									
11	-		·						
//		<del> </del>							
//									
11									
//									
//			-					_ ···	
_ / /									
//		<del></del>					artis.		
//									
11						-			
//			<del></del>			***			
11			-						
//							-		
/ /				· <del></del>					
//									

Presents from:  TB clinic / PMTCT / VCT / GP / other Art clinic / primary case clinic / im-patient / correctional / work / other  Wisc ex.NICAL STATUS  Typer patient bas. OR MAS EVER NAD, any of the lineases below, properly and properly an			L ASS											care		
Programment there, OR HASE SEVER HAD, any of the immenses below, and notice in stage 4, and price to account 2-90, they not entitled Count in a 500, they need HAVART Control of the Interest of the Interest of the Interest of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of Interest Se															correctional	/ work / other
Programment there, OR HASE SEVER HAD, any of the immenses below, and notice in stage 4, and price to account 2-90, they not entitled Count in a 500, they need HAVART Control of the Interest of the Interest of the Interest of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of the Interest Section of Interest Se	WHO CI	INICAL	STACING	ger week				ing sing			polaris.			A Helm Agen & Arm of		
Date   Clinical Features   Date   Clinical Features   Date   Clinical Features   Date   Clinical Features   Date   Persistent generalized lymphadenopathy   Persistent generalized limited lymphadenopathy   Persistent generalized limited lymphadenopathy   Persistent generalized limited lymphadenopathy   Persistent generalized lymphadenopathy   Persistent generalized lymphadenopathy   Persistent generalized limited	If vo	ur natien	t has . OR HA	S EVER	HAD, a	ny of th	ne illnesses	s belov	N,	If you	ır patie	ent had .	OR HA	S EVER HAD, a	any of the illn	esses below,
Persistent generalized lymphadesopathy Other: Other			tage 4, and	a CD4 (	count >	350,1	ney need			Clini				unit io + coop and	,	
Preumocyclis proved (formarly PCP)	7. 2 7 7 77 7		nt generalise	ed lympi	hadeno	pathy				5	He	rpes sim	plex vir	us lessions > 1 i	month	
Preumocyclis proved (formarly PCP)	Stage						<del></del>				Oe	sophage	al cand	lidiasis		
Minor musocuteneous conditions   Minor musocuteneous conditions		Woighte	loss <10% h	odv we	iaht					100	Pn	eumocys	tis jirov	eci (formerly PC	:P)	
Recurrent URTI	OF THE						,	_		13.49	Ko	posi's sa	rcoma			
Other  Welgin loss >10% body weight  Districtores >1 month  Oral candidisels  Froinged fever  Bedridden < \$50% / day for most of lest month  Cryptococcal meninglits  Control del cryptococcal del cryptococcal del cryptococcal del cryptococcal del cryptococcal del crypt				0 001.01					·	SUL SUL	HI	/ wasting	syndr	ome		
Other  Welgin loss >10% body weight  Districtores >1 month  Oral candidisels  Froinged fever  Bedridden < \$50% / day for most of lest month  Cryptococcal meninglits  Control del cryptococcal del cryptococcal del cryptococcal del cryptococcal del cryptococcal del crypt	<b>2</b> 1	Uncomp	licated herne	s zoste	r			-			· (	/ encept	alopati	ny		The second secon
Weight loss >10% body weight   September			noated norpe		•					- ig	Re	current r	neumo	nia		
Distribution   Dist			lace >10% b	ody wei	abt			$\dashv$		19	Cv				<u>,,, ,</u> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Cryptococcal meningitis  Cryptococcal meningitis  Cryptococcal meningitis  Cervical cancer  Lymphoma  Extra-pulmonary TB  Cother  Coth	* : *				9110					- 3	.*			tosporidiosis		
Cryptococcal meningitis  Cryptococcal meningitis  Cryptococcal meningitis  Cervical cancer  Lymphoma  Extra-pulmonary TB  Cother  Coth						<del> </del>				-	Be				last month	
Orsi hairly elucyclateds Prolonged fever Bedridden <50% / day for most of fast month  Umphoma  Extra-pulmonary TB  Other  Cohor:  REPRODUCTIVE REALTH  Pregnent Y N Trimester 1 2 3 Grav Para Pap smear result:  Date last used:  none / condom / injection / pill / other  Sign and symptoms os STI sidesy dysuria description:  TUPERCULOSIS SCREEN  Vear FFT3 or pulmonary  Treatment outcomes  Ever had Tb before?  Y N Pulmonary or extra-pulmonary  Date commenced treatment  Tag symptoms 1) Cough > 2 wks Y / N	(O)								<u></u>		-					
Orsi hairly elucyclateds Prolonged fever Bedridden <50% / day for most of fast month  Umphoma  Extra-pulmonary TB  Other  Cohor:  REPRODUCTIVE REALTH  Pregnent Y N Trimester 1 2 3 Grav Para Pap smear result:  Date last used:  none / condom / injection / pill / other  Sign and symptoms os STI sidesy dysuria description:  TUPERCULOSIS SCREEN  Vear FFT3 or pulmonary  Treatment outcomes  Ever had Tb before?  Y N Pulmonary or extra-pulmonary  Date commenced treatment  Tag symptoms 1) Cough > 2 wks Y / N	Stag		·		nciuaing	) Pneu	monia				·			inglus		
Prolonged lever   Bedridden <50% / day for most of last month   Extra-pulmonary TB   Chher   CD4 result	9 °	Oral hai	ry leukoplaki	a 				_		- 7	. ]	, i				
Pulmonary TB (current or in the last year)*   Other											1					
CD4 result	100	Bedridde	en <50% / da	y for m	ost of la	st mor	nth	_			i E	tra-pulm	onary	В	منته المستوانية والمستوانية والمستوانية والمستوانية والمستوانية والمستوانية والمستوانية والمستوانية والمستوانية	
REPRODUCTIVE HEALTH  Pregnent Y N   Trimester 1 2 3   Grav   Para   Pap smear result: Date:  Contraception:  Dete last used:  Done / Condom / Injection / pill / other  Signs and symptoms   1) Urethrat discharge/   2) vaginal   3) Scential   4) septial   5) Lower abdominal   RPR (date) + results   Tx completed   6s of today/   6s of to		Pulmona	ary TB (curre	nt or in	the last	year)*				( en   1 m	-	·			المستخلف	
Pergnent Y N   Trimester 1 2 3   Grav   Para   Pap smear result:   Date:		Other:									CI	04 result			<u> </u>	
TUBERCULOSIS SCREEN  Ever had TB before?  V N Pulmonary or extra-pulmonary  Treatment outcomes  Veer LeptB or pulmonary  Date commenced treatment  TB symptoms  1) Cough > 2 wks  Y / N V / N V / N  Smear date  Result  Culture / sensitivity date  Result  NUTRITIONAL SCREEN (Note;if BMI is less than 18.5 must refer to diablcian and nutritional programme)  Date of assessment:  / /  HISTORY.AND.EXAMINATION:  PLAN:  Respiratory Rate:  God Pit:  Date  Greened for Pit:  Date  Screened for offirmonazate  Y N  Date:  Date:  Date:  / /  Date:  Date:  / /  Date:  Date:  Date:  / /  Date:  Date:  Date:  / /  Date:  Date:  / /  Date:  Date:  / /  Date:  Date:  Date:  / /  Date:  Dat	Contracept none	ion: / con	dom /	injectio	1 /	pill	/ oth	sed:		<u> </u>				RPR (date)		
Year   EPTB or pulmonary   Treatment outcomes	os STI today	1	dysuria		discharg	eY/N	ulcers Y / N	\ <u> </u>	warts Y/N	p	ain Y /	N				Y/N
Ever had TB before?  Y N   If YES    Current TB	TUBÈRO	ULOS	S-SCREEN	je	***	• 1 de 9	en a reggi	· · ·			-			y i sinifan ee		
Current TB Y N Pulmonary or extra-pulmonary Date commenced treatment  TB symptoms today 1) Cough > 2 wks 2) Weight loss 3) Fever Y / N Y /				v	N1	"VE		Y	/ear		EPTE	or pulmon	ary		Treatment ou	utcomes
TB symptoms 1) Cough > 2 wks 2) Weight loss 3) Fever 4) Night sweats 5) Haemoptysis 6) Fatigue 7 / N 7	Ever had 1B	petore?		ī	IN.	11 12	°									
TB symptoms today Smear date Result  Culture / sensitivity date Result  Culture / sensitivity date Result  NUTRITIONAL SCREEN (Note:if BMI is less than 18.5 must refer to dictician and nutritional programme)  Date of assessment:  A. Weight: (kg)  B. Height (meters)  C. BMI = (Magnetics)  C. BMI = (Magnetics)  COL = (Magnetics)  Col =	Current TB			Υ	N	Pulmo	onary or ext	tra-pulr	nonary	D	ate cor	nmenced	treatmer	nt ·		
Smear date Result  Culture / sensitivity date Result  Culture / sensitivity date Result  Culture / sensitivity date Result  Culture / sensitivity date Result  Clinical indicatio of TB  Y / N  Date of assessment:		ms			vks											
Date of assessment:  / /  HISTORY AND EXAMINATION:  Temperature:  Heart Rale:  Blood Pressure:  Respiratory Rate:  Cuthmoxazole  Fluconazole  Other:  Screened for IPT:  Y N  Date:  Screened for cotrimoxazole  Y N  Date:  Screened for other / fluconazole  Y N  Date:  D	Smear dat	е						y date							catio	Y / N
HISTORY AND EXAMINATION:  Temperature: Heart Rate:   CD4 > 350 AND stage 1 - 3	NUTRIT	IONAL	SCREEN	(Note:i	fBMI is	less the	n 18.5 mus				itional	orogramn			-	
Temperature:   CD4 > 350 AND stage 1 - 3	Date of			A. W	/eight: (	kg)		B.H	leight (mete	rs)		-		everging every		····
Heart Rate:   CD4 < 350	HISTOR	Y AND	EXAMINA'	TION:	و بنايد	: ••• 3		'	a Commence	ala de la composición dela composición de la composición de la composición dela composición dela composición dela composición de la composición dela co		PLA	N:	e e	endrature of a	entre de la companya
Heart Rate:	1	:												stage 1 - 3		
Screened for IPT:  Date:  Screened for cotrimoxazole  Y N  Date:  Date:  Y N  Date:  Screened for cotrimoxazole  Y N  Date:  Screened for other / fluconazole  Y N  Date:  Screened for other / fluconazole  Y N  Date:  Da		ure:										1				<del></del>
Screened for IPT:  Y N  Date:  Screened for cotrimoxazole  Y N  Date:  Screened for cotrimoxazole  Y N  Date:  Screened for other / fluconazole  Y N  Date:  Screened for other / fluconazole  Y N  Date:  Da	Respiratory	Rate:							•			- 1				
Date:  Date:  Screened for cotrimoxazole  Date:  Date:  Oualifies / started  Y N  Date:  Date:  Date:  Oualifies / started  Y N  Date:	Screened for I	PT:			- h)	Quali	lies for IPT:							Started IPT		YN
Date:  Da	Date:						dy for cotrimoxa	zole		~			,, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>			YN
Date:  Da	Date :			Y	N	Date	-				······································		<del></del>	Date: Qualifies / started		
		ALIGNA / HUCONS		. Y	N	`	-						ΥN	Date;		f IV
	Print name:					Sign	ature:							Date:	, ,	

Total Date Result Other tests Date Result Nodes  Total Date Result Other tests Date Result Nodes  ALT lacemoglobin  CD4 If YES: Perfort TB work-up, record results in visit summary sheet  Total Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  Total Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary sheet  TOTAL Supplications of TB7 Y N If YES: Perfort TB work-up, record results in visit summary shee	4. CLINICAL If HAART is Indicated for	EVELU your patient ,use	TIONS FO	OR HAART OF decide whether there are an	TO RE-S	TART HAA	RT		
Tost Date Result Other tests Date Result Notes  ALT	Habistervier	ON	ar in a trin security in talk it at a gradual in	energe an income in the contract of Production and the Contract of Production and the Contract of Production and the Contract of Production and the Contract of Production and Contract					
Total Date Result Other tests Date Result Notes  ALT	your patient has ever had pr	evious HAAR I, det	ails the period when tal	ken , trealment changes <b>and th</b> e r	easons they stopped trear	nent: ♥			
Total Date Result Other tests Date Result Notes  ALT	<b>»</b>								
Total Date Result Other tests Date Result Notes  ALT									
Total Date Result Other tests Date Result Notes  ALT									
Total Date Result Other tests Date Result Notes  ALT									
ALT  Jaemoglobin  CD4  If YES: Perfom TB work-up, record results in visit summary sheet  If Total Control of the property of t	فقد من را ميدو در دومياهيان و ناوه ديد و هم خطاب (الله الله	marita de la maria de la composición de la composición de la composición de la composición de la composición d							
Table 1		Date	Result	Other tests	Date	Result		Notes	<del></del>
mptoms suspicious of TB? Y N If YES: Perfom TB work-up, record results in visit summary sheet  ### PERSONAL PROPERTY OF THE CONTROL OF THE CO									
INTERPORT SUSPECTORS INFECTOR IN THE NOTION IN THE STATE OF THE NOTION IN THE STATE OF THE NOTION IN THE STATE OF THE NOTION IN THE STATE OF THE NOTION IN THE STATE OF THE NOTION IN THE STATE OF THE S	aemoglobin								
Institutions suspicious of TB? Y N If YES: Perform TB work-up, record results in visit summary sheet  INSTITUTE SESSIMENT Imptorms Nausea / Vorniting / Diarrhoea / Severe loss of weight / Difficulty swallowing  Baseline BMI  INDATINGE  INDATI	CD4					-			
Institutions suspicious of TB? Y N If YES: Perform TB work-up, record results in visit summary sheet  INSTITUTE SESSIMENT Imptorms Nausea / Vorniting / Diarrhoea / Severe loss of weight / Difficulty swallowing  Baseline BMI  INDATINGE  INDATI	HUGERALIA					The second second second second second second second second second second second second second second second se			e ale
mptoms Nausea / Vomiting / Diarrhoea / Severe loss of weight / Difficulty swallowing  INICAL FACTORS INFERURNING REGIMENCIAGES  IT Treatment?  Y / N SHas had more than 1 month Y / N SHas had more than 1 month Y / N SHas had more than 1 month Y / N SHas had more than 1 month Y / N SHas had more than 1 month Y / N SHas had more than 1 month Y / N SHAS / S Y / N ARV 2  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N SHORE / S Y / N ARV 3  Severe peripheral Y / N Regimen Y / N Regimen Y / N Regimen Y / N Regimen Y / N Regimen	er ann an	s of TB?	Y N	If YES: Perfom TB w	ork-up, record res	ults in visit summ	ary sheet		
mptoms Nausea / Vomiting / Diarrhoea / Severe loss of weight / Difficulty swallowing  Baseline BMI   INCAL NOTE  I						ence in viole dumin	lary sneet		
NICAL EACTORS INFELLENCING RECINE NERFOLDS  B Treatment?  y / N  5 Has had more than 1 monit  y / N  6 BMI > 27.5  y / N  5 severe peripheral  y / N  8 Nother  y / N  1 Continuouszole  y / N  Continuouszole  int  int  Continuouszole  int  Continuouszole  int  Continuouszole  int  Continuouszole  y / N  Regimen  y / N  ASSISSIENTHOPOVERALS READINESS CIR ABI  atture:	tain belletinder alle versichen berieben Lieben 30 fere in 18 mil	elektrika di editak elektrika.	and the state of the control of the state of	ioea / Severe loss o	weight / Difficul	tv swallowing	de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la Companya de la		
VICALIFACTORS INFELIENCING REGIMENTCHOICE TB Treatment?  y / N	INGALNORES							BMI	
TB Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)						) B	<b>~</b>		
TB Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)						,			
### Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)									
TB Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)									
TB Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)									
TB Treatment?    S.Has had more than 1 month of HAART? (excluding PMTCT or PEP)	Viola de Verrales	(เกียนแลงไลม์	versional version						
gnant?  y / N  6.BMI > 27.5  y / N  ARV 1  ARV 2  ARV 3  a history of pychiatric ss?  y / N  8.Other  y / N  Cotrimoxazole  Fluconazole  IPT  Clinically ready  y / N  Regimen  y / N  Regimen  y / N  ARV 1  ARV 2  ARV 3  Cotrimoxazole  Fluconazole  PT  Clinically ready  y / N  Regimen  y / N  Regimen	The second secon	5.Ha	as had more than 1	month	PLAN:			The second second	
a history of pychiatric ss?  ARV 3  ARV 3  ARV 3  ARV 3  ARV 3  ARV 3  Cotrimoxazole Fluconazole IPT  Chosocial readiness (see section 7)  MicAlEJFACTORS INFRUENCING REGIMEN GHOIGE  Chosocial readiness (see section 7)  MicAlEJFACTORS INFRUENCING REGIMEN GHOIGE  Chosocial readiness (see section 7)  Y / N  Clinically ready  Y / N  Regimen  Y / N  ARV 3  ARV 3  ARV 3  Cotrimoxazole Fluconazole IPT  Chosocial readiness (see section 7)  Y / N  Regimen  Y / N  ARV 3	gnant?	· / · · ·		Y /	N ARV 1				
a history of pychiatric serior	s severe peripheral		ther	Υ /					
Properties (See Section 7)  The fluctonazele IPT  Chosocial readiness (see Section 7)  The fluctonazele IPT  The fluctonazele IP	a history of pychiatric		her	Y /					
Chosocial readiness (see section 7)  Y / N  Clinically ready  Y / N  Regimen  ASS SSMENT(0)FIOVERVALE READINGS SOPEMANTAL  ature:	ss?	Y / N		Y / I	. 1				
chosocial readiness (see section 7)  Y / N  Clinically ready  Y / N  Regimen  Y / N  ASS SS HENROF TO VERY ARE READINGS TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO PROVE TO VERY AREA TO VERY					IPT	WE THINK TO THE WOOD OF			Selection of the select
men factors (clinical factors influencing choice)  Y / N  Regimen  Y / N  ASS SS // H / N (OPTO // PRANT READING STOPE // AND REGIMEN  ature:				7-(e)(e)5					tit i
ature:	chosocial readines	s (see section	n 7)	Y / N	Clinically ready			Y	' / N
######################################	men factors (clinic	al factors infl	uencing choice)	Y / N	Regimen				
ature:			27/35133	illavar (oleto) vietavale	azadijulasago	igaviit ":"			
Date: / /	ature:					ar valle a laterativa array time a tolk to pel media latera da	to the second second second second second second second second second second second second second second second	pade an Maritman an mad	

.

Date: N / # N/D: N / D: Weight Temp / Height Months on Art Months on regimen History and examination Notes STI screen FP / Condoms TB Rx TB suspect TB status Assessed No signs Months on TB Rx TBM / C / S CD4 (CD4%) Investigations Viral Load ALT HB / WCC / PLT Other investigation results (inc.XR) HIV conditions / OIS, TB & other conditions 2 Assessment 3 3 4 Adverse event / grade Adverse event / grade Stage chances Notes OUT IN H H IN OUT Adherence & Ξ Counselling FREEDOM CHARACTER AND THE CONTROL 中华的现在分词 计 ARV 1 Plan and treatment ARV 2 ARV 3 Drugs and dosages Contrimoxazole INH Fluconazole Referred Date of next visit Signed (initialed) 1 Date Data Capturer Signed

		<del> </del>
);	/ / N/D:	/ / N/D:
		,
·		
		·
	1	1
· · · · · · · · · · · · · · · · · · ·		2
	3	3
	4	4
		·
,		
IN OUT _	IN OUT _	IN OUT
IN OUT E	IN OUT E	IN OUT #
No. of the control of		
,		
1 1	1 1	1 1
1 1	1 1	I I

					i	1 1	ı
#			Date: / /	· · · · · · · · · · · · · · · · · · ·			N N
Ι"		•	N/D:			N / D:	
$\vdash$	<b></b>	Weight					
1							
		Temp / Height				*	
		Months on Art				<u> </u>	39.
		Months on regimen					
1		-					
Ę							
la B					ļ		
ΙΈ		•			ŀ		
œ	1	Notes '					
9							
12					ŀ		
History and examination							$\dashv$
15,		STI screen					
St	1	FP / Condoms	·		İ		
王		TD etetue	<u> </u>				
		TB status		<del></del>			-
	]	Months on TB Rx					
-	1	TB M / C / S					
	<b> </b>						$\Box$
	<u></u>	CD4 (CD4%)					<del></del>
2	1						
Investigations							
at	1	ALT					
Iĝ		HB / WCC / PLT					l
es							
≥		Other investigation results (inc.XR)					
-		results (Inc.AR)					
1					,		165
		- S	1			1	1
		중 축 조					
1	ļ	5 5 €	2			2	2
12		HIV conditions / OIS, TB & other conditions	1				
Assessment		2 1 2	3			3	3
LS	1	5 6 8					
S		HIV OIS,				4	4
SS	1	Ŧ O	4				
4							
		Adverse event / grade			<u> </u>		
1		Adverse event / grade					Ì.
	-	Stage chances					
		Stage charices				·	
Г			1				
l	ĺ						
		Notes					
1	1	Notes					ļ
1						· .	
1							
						[ ]	
		Adherence &		IN OUT	Æ	IN OUT	표
1	1	Counselling			-	V   V	
1	:	ARV 1	/				<del></del>
<u> </u>	i	ARV 2				1	
Plan and treatment	×	. ARV 3					
9	Drugs and dosages	. ARV 3			т	<del> </del>	
=	į į į	Contrimoxazole			1		
2	ä	HAI					
1 6	i i ii	Fluconazole	1	++-	+		
<u> </u>	i   ''			-	+		
٥	-	Referred					
		Date of next visit	I I		L	1 1	
	ļ	Signed (initialed)	Nurse/Doctor				
	-	Date	1 1			1 1	
		<u> </u>	<del>                                     </del>	Data Capture	or .		
		Signed		·			

	·	*.
1 1	, ,	
	N/D:	/ / N/D:
		N/D:
<u> </u>		
		•
e		
•		
-		
		·
		,
	1	[1
	2	2
	3 .	3
		,
	4	
	4	4
·		
IN OUT _	I ny Lour-I	
. IN OUT ₹	IN OUT E	IN OUT E
	· · · · · · · · · · · · · · · · · · ·	
		16 17 17
	, , + + + +	<del></del>
	1 1	
		·
		· · · · · · · · · · · · · · · · · · ·
		1 1

Date: # N/D: N / D: Weight Temp / Height Months on Art Months on regimen History and examination Notes STI screen FP / Condoms TB status Months on TB Rx TBM /C/S CD4 (CD4%) Investigations ALT HB / WCC / PLT Other investigation results (inc.XR) OIS, TB & other conditions HIV conditions / Assessment 3 10 Adverse event / grade Adverse event / grade Stage chances Notes OUT OUT 푼 Adherence & 픐 Counselling ARV 1 Plan and treatment ARV 2 Drugs and dosages ARV 3 Contrimoxazole INH Fluconazole Referred 1 Date of next visit Signed (initialed) 1 Date Data Capture Signed

		7
1 1	1 1	
	N/D:	N/D:
		W. D.
p»		
•		
		,
·		
	·	
-		
· ·		
W. V.		
	<u> </u>	
	1	
		1
	2	2
· · · · · · · · · · · · · · · · · · ·	3	
	3	3
	7/17	
	4	4
	·	
İ		
IN OUT ₹	IN OUT E	IN OUT E
▼   ▼   −		▼ ▼  ₺
<u></u>		
' /	1 1	1 1
	,	
<del></del>		

.

Date: # N/D: N / D: Weight Temp / Height Months on Art Months on regimen History and examination Notes STI screen FP / Condoms TB status Months on TB Rx TB M / C / S CD4 (CD4%) Investigations ALT HB / WCC / PLT Other investigation results (inc.XR) HIV conditions / OIS, TB & other conditions 2 2 Assessment 3 3 4 4 Adverse event / grade Adverse event / grade Stage chances Notes OUT Adherence & Counselling OUT 품 표 ARV 1 Plan and treatment ARV 2 Drugs and dosages ARV 3 Contrimoxazole INH Fluconazole Referred Date of next visit Signed (initialed) Date Signed

	<b></b>	
·1 1		1 1
	N/D:	N/D:
*		
_		
		· · · · · · · · · · · · · · · · · · ·
	·	
		·
	<u> </u>	
	1	1
	•	1
	2	2
·		
	3	3
	4	
		4
·		ļ
IN OUT E	IN OUT E	IN OUT ₹
		<b>V</b>
	the state of the s	
	.1 1	

Date: # N/D: N/D: Weight Temp / Height Months on Art Months on regimen History and examination Notes STI screen FP / Condoms TB status Months on TB Rx TB M / C / S CD4 (CD4%) Investigations ALT HB / WCC / PLT Other investigation results (inc.XR) TB & other conditions 2 Assessment 3 Adverse event / grade Adverse event / grade Stage chances Notes Adherence & Counselling OUT OUT IN 풊 표 ARV 1 Plan and treatment ARV 2 Drugs and dosages ARV 3 Contrimoxazole INH Fluconazole Referred Date of next visit 1 Signed (initialed) 1 1 Data Capturer Signed

	/ / / N/D:	
	N/D:	N/D:
·		
	No. of the second secon	
	1	·
	1.	
	· · · · · · · · · · · · · · · · · · ·	
	·	
	11	1
	2.464.99	•
·	2	2
	3	
	·	3
	4	4
	÷	
•		
IN OUT _	IN COUT	
IN OUT E	IN OUT ₹	IN OUT
1 1		
		1 1

Date: # N/D: N / D: Weight Temp / Height Months on Art Months on regimen History and examination Notes STI screen FP / Condoms TB status Months on TB Rx TB M / C / S CD4 (CD4%) Investigations ALT HB / WCC / PLT Other investigation results (inc.XR) HIV conditions / OIS, TB & other 1 conditions 2 2 Assessment 3 Adverse event / grade Adverse event / grade Stage chances Notes OUT OUT Adherence & IN 표 표 Counselling ARV 1 Plan and treatment ARV 2 Drugs and dosages ARV 3 Contrimoxazole INH Fluconazole Referred Date of next visit Signed (initialed) Date Signed

A.A.

N/D: N/D: 2 2 3 3 4 4 표 IN OUT 표 1 1

The part of North	5.SOCIAL				.l == -•	nto					(Per	ord the	date this soci	al assessi	ment was	s made)		/	/	/
Comments   Comments			s the need fo	r socia	u assi:		al dwelling	/ form	nal hous	e / hostel /			7				Re	frigerato	r: Y	N
Interested the process of the proces	of dwelling? (please				12						is curren	tly partn	<u> </u>		N T	ls curre			<del></del>	
IN albutis - /+	Number of adults n household								`	Y N	husband/	wife?	•	Y	of			-, -,,,,,,,		
Validation   1/4	Age and HIV status o	hildren					1	1			T			V///	///	///	77	///		///
Interest of the control of the contr	Own children	Age				#***					Other chi	ldren in	household			[[]		///		<i>[[_</i>
HIV Status - /- /- /- /- /- /- /- /- /- /- /- /- /	HIV etatue	-/+											Age							
tax patient disclosed HIV status	na orarno				十			1				HIVS	Status -/+					_		
Coursent growth of the season	n household			L	<del>_</del>	, <sub>k1</sub>	I To	o whom	:		1			L	<b>!</b>					1
Dualities for great?  Y N DG Child Other.  Current Current allocitorid use y N N DG Child Other.  Current allocitorid use y N N DG Child Other.  Provide the second or great of the second or great definition of the second or great definition or great definition.  Provide the second or great pathwale commonly the provide the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or great pathwale commonly the second or	las patient disclos	sed HI\	/ status		· ·	IN.														
Current alcohold use a substitution of the sub	Source of income?	? (circle	e)			employ	ed / g	grant	/ pe	ension	/ friend	s or fam	iny 			<del></del>				
Current ing use a doubt of use your entiting to a doubt of the second power and a doubt of the	Qualifies for grant	1?	Y	N	DG							Re	eceicing grant	YN		Ap	plication	Submitt	,	
Referred   Date	Current		-		aire	Have your	ou ever felt r drinking	you sho	ould cut	down	ΥN			ou by critic	ising	· ·			Cage	e Sco
Referred   Date	-			N	AGE	Have	you ever f	felt guil	lty or ba	ad	ΥN	Have y	ou ever had a d dy your nerves	irink first thi or to get rid	ng in the n of a hang	noming over				
Adherence Planning Other Name and contact details for treatment buddy:  Patient agreed it home visit Y N What is clients undentanding (in their own words) for warning MART?  7.PSYCHO-SOCIAL READINESS  If it has been decided MART? own safety be standed (seeds on this placeties if your patient is psychologically and socially impreed for MART?    Name of decided MART? own safety be standed (seeds on 4) are this patient is psychologically and socially impreed for MART?    Name they attended all required counselling sessions?   Y   N   N   N   N   N   N   N   N   N	Referral				ا ن	Labout	, 00, 0,,,,	Appoir	ıtment:			<u> </u>	<del></del>	<del></del>						
Session Date/s Counsellor / Session / Reveal of understanding)  General HIV Education and Healthy Living  Antiretroviral Therapy  Adherence Planning  Other  Name and contact details for treatment buddy:  Patient agreed ti home viet Y N  What is cleate understanding (in their cone words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If has been decided HAART can safely for alumed (reaction of use files section to help decide if your patient is psychologically and socially prepared for HAART.  Neroethart NOTE: The cheels below are ONLY a prempt for the health care worker to cheek that the patient is:    Neroethart NOTE: The cheels below are ONLY a prempt for the health care worker to cheek that the patient is:   A point modified.   It has received HIV / ART education and child have decided appoint    Y	Clinic						<u> </u>	Date					:							
Seeseion Date/s Counsellor / group attended? Comments (c.g. motivation, level of understanding)  General HIV Education and Household all required counselling sessions? (c.g. motivation, level of understanding)  Antiretroviral Therapy  Adherence Planning  Other  Name and contact details for treatment buddy:  Patient agreed ti home visit Y N  Name of community health worker:  Y N  Attends a support group Y N  What is clemis understanding (in their own words) for warning HAAKY?  T.P.SYCHO-SOCIAL READINESS  If it has been decided MAART can safely be started feection 4) use this saction to help decide if your relief in the properties of a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a patient is:  A positionally a property of the health cane worker to chack that the patient is:  A positionally a patient is:  A positionally a positional page of social support  A positionally a page of social support  A positionally a page of social support  A positionally a page of social support  A positionally a page of social support  A positionally a page of social support  A positionally a positional page of social support  A positional page of social support  A positional page of social support  A positional page of social support  A positional page of social support  A positional page of social support  A positional page of social support	6. PRE - A	RT ecord to	COUN:	SEL counsel	LIN ling his	lG tory														
General HIV Education and Healthy Living  Antiretroviral Therapy  Antiretroviral Therapy  Antiretroviral Therapy  Antiretroviral Therapy  Other  Name and contact details for treatment buddy:  Patient agreed ti home violit  Y N  What is clients understanding (in their own words) for wanting MAATT?  7.PSYCHO-SOCIAL READINESS  If it has been deaded HAATC an astiny be standed (section 4) use this section to help decide if your potient is psychologically and socially prupaned for HAATC.  BEFORTANT NOTE: The choice below are ONLY a prompt for the heads care worker to schook that the polant is: a) self motivored. By International HAATC an astiny be standed (section 4), b) has received HIV FATC education and of her degree of social support  Y N  Have they attended all required counselling sessions?  (see above)  Have they disclosed to anyone?  Have they been attending the clinic regulary?				_	_	Co					Commen	ts vation	level of upo	leretandi	na)					
Antiretroviral Therapy  Adherence Planning  Other  Name and contact details for treatment buddy:  Patient agreed ti home visit  Y N  What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  ## has been decided MAART can safety be started (section 4) use this section to help decide #your patient is psychologically and society prepared for HAART.    MPORTANT NOTE: The checks below and ONLY a prompt for the neath care worker to check that the patient is:   A) will motived, b) has received HV ART education and c) has degree of social support    Have they attended all required counselling sessions?	-					gro	oup	$\dashv$	attend	iea?	(e.g. moti)	vauon ,	ieaci oi nije	.ci stai iui	y/			<u></u>		
Adherence Planning  Other  Name and contact details for treatment buddy:  Patient agreed it home wist Y N  What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N    It has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N    It has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N    It has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N    It has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N    It has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a support group Y N   International Company of the patient is:   Attends a	General HIV Ed Healthy Living	lucatio	on and																***	
Other  Name and contact details for treatment buddy:  Patient agreed ti home visit  Y N  Name of community health worker:  Visit  Y N  What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section to help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and socially prepared for HAART.  Starting Annual Community (Section 1) help decide if your petient is psychologically and social support in the health of t	Antiretroviral Th	nerapy	<i>(</i>				_ <del></del>													
Name and contact details for treatment buddy:  Patient agreed ti home visit Y N  What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Review started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.	Adherence Pla	ınning	•																•	
Patient agreed ti home visit  Y N  What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Name of community health worker:    Attends a support group   Y N	Other_																			-
What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use	Name and con	itact d	etails for tre	eatme	nt bu	ddy:					<u> </u>									
What is clients understanding (in their own words) for wanting HAART?  7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Harp: (c. 1610/5/Levo)/Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Social Hart (section 4) use				<del></del> -												<del></del>				
7.PSYCHO-SOCIAL READINESS  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.    Section Interview Colleges (Conception of the health care worker to check that the patient is:   a) self motived   b) has received HIV / ART education and c) has degree of social support    Have they attended all required counselling sessions?   Do they have a treatment buddy?		ti hon		- 1	Name	e of con	nmunity l	neaith	work	er:						s			Y	N
7.PSYCHO-SOCIAL READINESS  Date: / /  If it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Revite: Haart (section 5) (section 6) (secti	What is clients unde	erstandir			) for wa	nting HA	ART?							•		1_				
if it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Revize: introduction and clother control of the health care worker to check that the patient is:  a) self motived, b) has received HIV / ART education and c) has degree of social support  Y Have they attended all required counselling sessions?  (see above)  Have they disclosed to anyone?  Have they been attending the clinic regulary?																				
if it has been decided HAART can safety be started (section 4) use this section to help decide if your patient is psychologically and socially prepared for HAART.  Revize: introduction and clother control of the health care worker to check that the patient is:  a) self motived, b) has received HIV / ART education and c) has degree of social support  Y Have they attended all required counselling sessions?  (see above)  Have they disclosed to anyone?  Have they been attending the clinic regulary?	7 DOVOU	<u> </u>	CIAL	DE	ΔD	INES	S	**	· · · · · ·	<del></del>						Date:		1		/
IMPORTANT NOTE: The checks below are ONLY a prompt for the health care worker to check that the patient is:  a) self motived , b) has received HIV / ART education and c) has degree of social support  Y Have they attended all required counselling sessions? (see above)  Have they disclosed to anyone?  Have they disclosed to anyone?  Have they been attending the clinic regulary?						ction 4) u	se this sect	tion to h	elp deci	de if your pa	tient is psychol	logically a	nd socially prep	ared for HA						
A) self motived, b) has received HIV/ART education and c) has degree of social support  Y Have they attended all required counselling sessions?  (see above) Have they disclosed to anyone?  Have they disclosed to anyone?  Have they been attending the clinic regulary?					*** ****	/7¢3	llaviralning	eli lices	odo <i>j</i> e	Chovojii	larceesinge	alk am	नीताः (तिहिन्दरः <b>न</b> ी	inir .	,		444	سف دیارسمیتند		
Have they attended all required counselling sessions?  (see above)  Have they disclosed to anyone?  Y  Do they have a treatment buddy?  Have they been attending the clinic regulary?					IMPO	RTANT N a) s	OTE: The c	hecks b	eiow are s receive	e <b>ONLY</b> a pr ed HIV / ART	ompt for the he education and	ealth care I c) has d	worker to check egree of social	that the pa	atient is:				-1	
(see above)  Have they disclosed to anyone?  Have they been attending the clinic regulary?																			Y	
Have they disclosed to anyone?  Have they been attending the clinic regulary?	<b>.</b>	tende	ed all requ	ired o	couns	selling	sessior	ns?			Do they I	have a	treatment	buddy?	?					
If the answer to all the above questions is YES then the patient is ready commence HAART		sclos	ed to anyo	one?							Have the	ey bee	n attending	g the cli	nic reg	ulary?				
			lf t	the a	nswe	er to al	I the ab	ove c	uesti	ons is Yl	ES then th	e patie	ent is read	y comm	ence F	IAART				

8. Notes of Details	
Use this to make any extra notes regarding change of patient's Physical add	dress or Contact telephone number
	<u> </u>
	<u> </u>
9.Notes (continued) Use this section to make any extra notes regarding the patient	
	<del></del>
•	
legenting gegently of was not the proposition assumptions at the public between the first of the contract of the proposition of the public between the public of the public between the	galgerin vog vi <sup>t</sup> mer unggregeringerendig vig geginner i

9.Notes (continued)	
Use this section to make any extra notes regarding the patient	<del></del>
- 1-	•
and the second s	
	· · · · · · · · · · · · · · · · · · ·
	,
· 	
	·
	· · · · · · · · · · · · · · · · · · ·
·	
	. *
M	

9.Notes (continued)  Use this section to make any extra regarding the patients	
	·
·	

9.Notes (continued) Use this section to make any extra regarding the patients	
	•
	÷
·	
	·
, , , , , , , , , , , , , , , , , , , ,	



HAST UNIT
230 Prince Alfred Street
Pietermaritzburg
3200

Tel.No.: (033) 341- 4000 www.kznhealth.gov.za

	ITEM NO.	DESCRIPTION	1
			-
40.	23-16502	TICK REGISTERS A2 (520 X 297)  300 Pages Text black throughout 75GSM white board	
		Binding buckram, colate & staple Hand numbering Cover 250GSM glos  Packaging Unit: Each	i i
	ITEM NO.	DESCRIPTION	
		PAEDIATRIC CLINICAL CHART (ARV's)	-0.04
41.	23-29054	Cover: 160 GSM card yellow (paediatric) B4 size Printing on cover: coat of arms and title full colour Insert: 80g, 8 pages, A4 printed back to back	
		Packaging Unit: Each	
***************************************	ITEM NO.	DESCRIPTION	
***************************************		ADULT CLINICAL CHART (ARV's)	
42.	23-29051	Cover: 160 GSM card yellow (paediatric) B4 size Printing on cover: coat of arms and title full colour Insert: 80g, 8 pages, A4 printed back to back	
	ITEM NO.	Packaging Unit: Each  DESCRIPTION	,
i	Liit ito.	DEGOTIF TION	-
en de en en en en en en en en en en en en en	23-29055	Size: A3 Landscape Pre-press: Design to be done by printer Printing & Paper Cover Front: Printed CMYK both sides on G Print (Gloss), 300gsm, White Separating Sheets (x3): Emtini Liner, 235gsm, Kraft (not printed) Admissions (x75): Printed Black both sides on Cascade Bond, 80gsm, Pink	
43.	23-29055	Discharge (x75): Printed Black both sides on Cascade Bond, 80gsm, Blue Death (x15): Printed Black both sides on Cascade Bond, 80gsm, Yellow  Cover Back: Malgray (Chipboard) (1,170mic), 700gsm, Grey (not printed)  Finishing: hinged and wire stiched-4 wires.  Binding Books Trimmed to size Black Book Cloth on Spine	
AND AND PARTY AND ASSESSED ASSESSED.	·	Other Material: Insert Ribbons Pink, Blue, Yellow Despatch: Shrink wrapped & Boxed and deliver to one address in Pietermaritzburg Packaging Unit: Each	
	· · · · · · · · · · · · · · · · · · ·		
	ITEM NO.	DESCRIPTION	
44.	01-02401	FILE COVERS GENERAL File Cover General Buff 560 x 350mm - Pkt of 50 Printed one side only in black ink. Kraft Liner Material 225 GSM Size: 350mm x 560mm Colour: Brown Scored 220MM X 440MM from left hand edge not folded	
44.	01-02401	File Cover General Buff 560 x 350mm - Pkt of 50 Printed one side only in black ink. Kraft Liner Material 225 GSM Size: 350mm x 560mm Colour: Brown	

1 14



DIRECTORATE: KCD HEALTH DISTRICT OFFICE

Physical Address: 2<sup>nd</sup> Lood Avenue ,Kuleka,& Chrome Cresent Corner ,Empangeni Rall,Old Telkom Building Postal Address: Private Bag x 20034
Tel: 035 7870631 Fax: 035 787 0641 Email: Nokulunga.Mhlongo@kznhealth.gov.za
www.kznhealth.gov.za

QUOTATION NO.	ZNQ:KCD/194/24-25	
QUOTATION DESCRIPTION	STATIONARY	
BIDDER NAME		

#### **EVALUATION CRITERIA:**

The Department will evaluate quotation received after the closing date and time using three (3) stages,

Stage 1: Administrative, Compulsory and Mandatory Requirements; Stage 2: Compliance with specifications

Stage 3: Price and Preference Points System

#### STAGE 1: ADMINISTRATIVE, COMPULSORY COMPLIANCE AND MANDATORY REQUIREMENTS

NO.	REQUIREMENTS	INCLUDED IN THE PUBLISHED DOCUMENT?	TO BE RETURNED BY BIDDER/ TENDERER?
	Administrative Compliance	1	
1.	PARTICULARS OF QUOTATION	YEŞ	YES
2.	OFFICIAL PRICE PAGE FOR QUOTATIONS OVER R2 000.01, MUST BE CACLULATED CORRECTLY AND IN COMPLIANCE WITH SARS REQUIREMENTS	YES	YES
3.	BIDDER'S DISCLOSURE (SBD4)	YES	YEŞ
4.	GENERAL CONDITIONS OF CONTRACT (GCC)	YES	YES
5.	SPECIAL CONDITIONS OF CONTRACT (SCC)	YES	YES
6.	PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2022 (SBD 6.1)	YES	YES
	Compulsory Compliance		
7.	SUPPLIER UPDATED CIPC REGISTRATION DOCUMENTS	NO	YES
8.	A B-BBEE STATUS LEVEL VERIFICATION CERTIFICATE/ SWORN AFFIDAVIT (For EMEs& QSEs)	NO	NO
9.	COPY OF CENTRAL SUPPLIER DATABASE COMPLIANCE REPORT (CSD)	NO	NO
	Mandatory Requirements		,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10.	ALL DOCUMENTS TO BE RETURNED FULLY AND ACCURATELY COMPLETED	YES	YES
11	SAHPRA LICENSE	YES	YES

Note: This relates to administrative, compulsory and mandatory returnable documents which must be fully completed, and submitted, should you fail to submit any of the above returnable documents, your offer will be treated as non-responsive and will not proceed to the next stage of evaluation. The department reserve a right to verify validity of

INITIAL HERE M.

#### **STAGE 2: CAPACITY TO DELIVER**

1.	Proof of quotations where you will get all items quoted for on ZNQ /KCD 194 /24-25 may be required and failure to provide such information may result to your quotation being disqualified.	
2.	If there is valid proof that the bidder was previously issued with an order and failed to deliver without acceptable reasons, the bidder will be treated as a defaulter and will not progress to the next stage of evaluation.	

#### **Delivery Period**

The goods and services quoted for are required to be delivered within a period of **04 weeks** unless unforeseen circumstances may arise and reported timeously.

It is imperative to complete the delivery period field on the quotation form. All quotations returned with blank field on delivery period will be disqualified.

### STAGE 3: COMPLIANCE WITH SPECIFICATION

#### Requirement

The bidder / Tenderer to confirm that the item to be supplied comply with the attached specification, should you fail to indicate with yes, it will mean, you do not comply and your quotation will not progress to the next stage of evaluation

#### **STAGE 4: PRICE AND PREFERENCE POINTS**

The value of this quotation is estimated not to exceed **R 500 000** (inclusive of all applicable taxes), therefore the 80/20 preference point system shall be applicable. Points for this quotation will be awarded for:

CATEGORY	POINTS
PRICE	80
SPECIFIC GOALS	20
Total points for Price and must not exceed	100

The Department has identified the following specific goal:

Specific Goal	Number of Points allocated	Proof To Claim Specific Goal (Returnable Documents)		
RCP GOAL: full points allocated to promote enterprises owned by Youth	20	Ownership Certificate issued by the Companies and Intellectual Property Commission (CIPC).		
		The Department will download CSD to verify this information.		

## STAGE 5: OBJECTIVE CRITERIA IN TERMS OF SECTION 9.1.3 OF THE DEPARTMENTAL PRERENTIAL PROCUREMENT POLICY VERSION 2 (SUBMISSION OF SAMPLE)

- 1. At least three bidders who scored the highest points will be required to submit samples, the institution will only accept and award compliant sample.
- 2. Should all three bidders fail to submit sample, the next three highest scoring bidders will be requested to submit samples
- 3. Samples will be requested via email.

<b>EVALUATION CRITE</b>	RIA AND SPECIFICA	TION APPROVED BY			
Official	Title (Ms/ Miss/ Mrs/ Mr/Dr)	Surname	Initials	Date	Signature
End User Representative	Mr	Mkhalile	MU	applioli	War
SCM Official	Miss	Mhlongo	NN	Zext10(11	600

## **SEE BELOW SPECIFICATION DOCUMENT**

Marian No.